

EXPONENT INC  
Form 10-K  
February 22, 2019

UNITED STATES

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-K**

Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 28, 2018.

**OR**

Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from \_\_\_\_\_ to \_\_\_\_\_.

**Commission File Number 0-18655**

**EXPONENT, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

**77-0218904**

(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

**149 Commonwealth Drive, Menlo Park, California 94025**

(Address of principal executive offices) (Zip Code)

**(650) 326-9400**

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

| <b>Title of Each Class</b>                | <b>Name of Each Exchange on Which Registered</b> |
|---|--|
| Common Stock, \$0.001 par value per share | The NASDAQ Stock Market LLC                      |

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes  No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes  No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Edgar Filing: EXPONENT INC - Form 10-K

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer", "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

The aggregate market value of the common stock held by non-affiliates of the registrant based on the closing sales price of the common stock as reported on the NASDAQ Global Select Market on June 29, 2018, the last business day of the registrant's most recently completed second quarter, was \$2,136,924,922. Shares of the registrant's common stock held by each executive officer and director and by each entity or person that, to the registrant's knowledge, owned 10% or more of registrant's outstanding common stock as of June 29, 2018 have been excluded in that such persons may be deemed to be affiliates of the registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

The number of shares of the registrant's common stock outstanding as of February 15, 2019 was 51,498,369.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant's Definitive Proxy Statement for the registrant's 2019 Annual Meeting of Stockholders to be held on May 30, 2019 are incorporated by reference into Part III of this Annual Report on Form 10-K.

**EXPONENT, INC.**

**FORM 10-K ANNUAL REPORT**

**FISCAL YEAR ENDED DECEMBER 28, 2018**

TABLE OF CONTENTS

|   | <b>Page</b> |
|---|-------------|
| <b><u>PART I</u></b>  |             |
| <u>Item 1. Business</u>   | <u>3</u>    |
| <u>Item 1A. Risk Factors</u>  | <u>13</u>   |
| <u>Item 1B. Unresolved Staff Comments</u>   | <u>17</u>   |
| <u>Item 2. Properties</u>   | <u>17</u>   |
| <u>Item 3. Legal Proceedings</u>  | <u>17</u>   |
| <u>Item 4. Mine Safety Disclosures</u>  | <u>18</u>   |
| <b><u>PART II</u></b>   |             |
| <u>Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</u> | <u>18</u>   |
| <u>Item 6. Selected Financial Data</u>  | <u>20</u>   |
| <u>Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>                        | <u>20</u>   |
| <u>Item 7A. Quantitative and Qualitative Disclosures About Market Risk</u>  | <u>30</u>   |
| <u>Item 8. Financial Statements and Supplementary Data</u>  | <u>31</u>   |
| <u>Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</u>                         | <u>31</u>   |
| <u>Item 9A. Controls and Procedures</u>   | <u>31</u>   |
| <u>Item 9B. Other Information</u>   | <u>31</u>   |
| <b><u>PART III</u></b>  |             |
| <u>Item 10. Directors, Executive Officers and Corporate Governance</u>  | <u>31</u>   |
| <u>Item 11. Executive Compensation</u>  | <u>32</u>   |
| <u>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</u>              | <u>32</u>   |
| <u>Item 13. Certain Relationships and Related Transactions, and Director Independence</u>                                   | <u>32</u>   |
| <u>Item 14. Principal Accounting Fees and Services</u>  | <u>32</u>   |
| <b><u>PART IV</u></b>   |             |
| <u>Item 15. Exhibits, Financial Statement Schedules</u>   | <u>33</u>   |
| <u>Exhibit Index</u>  | <u>61</u>   |
| <u>Signatures</u>   | <u>64</u>   |

**FORWARD-LOOKING STATEMENTS**

This Annual Report on Form 10-K contains, and incorporates by reference, certain “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995, and the rules promulgated pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended), including but not limited to statements regarding future growth and market opportunities, revenue, margins, headcount, utilization and operating expenses, that are based on the beliefs of the Company’s management, as well as assumptions made by, and information currently available to, the Company’s management. Such forward-looking statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. When used in this document and in the documents incorporated herein by reference, statements other than statements of current or historical fact are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “continue”, “could”, “may”, “plan”, “expect” and similar expressions, as they relate to the Company or its management, identify certain of such forward-looking statements. Such statements reflect the current views of the Company or its management with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance, or achievements could differ materially from those expressed in, or implied by, any such forward-looking statements. Factors that could cause or contribute to such material differences include the possibility that the demand for our services may decline as a result of changes in general and industry specific economic conditions, the timing of engagements for our services, the effects of competitive services and pricing, the absence of backlog related to our business, our ability to attract and retain key employees, the effect of tort reform and government regulation on our business, and liabilities resulting from claims made against us. Additional risks and uncertainties are discussed in this Annual Report under the heading “Risk Factors” and elsewhere.

The inclusion of such forward-looking information should not be regarded as a representation by the Company or any other person that the future events, plans, or expectations contemplated by the Company will be achieved. The Company undertakes no obligation to update or revise any such forward-looking statements.

## PART I

### Item 1. Business

#### GENERAL

Exponent, Inc., together with its subsidiaries, (“Exponent”, the “Company”, “we”, “us” and “our”) is a science and engineering consulting firm that provides solutions to complex problems. Our multidisciplinary team of scientists, engineers, business and regulatory consultants brings together more than 90 different technical disciplines to solve complicated issues facing industry and government today. Our services include analysis of product development, product recall, regulatory compliance, and the discovery of potential problems related to products, people, property and impending litigation.

The history of Exponent, Inc. goes back to 1967, with the founding of the partnership Failure Analysis Associates, which was incorporated the following year in California and reincorporated in Delaware as Failure Analysis Associates, Inc. in 1988. The Failure Group, Inc. was organized in 1989 as a holding company for Failure Analysis Associates, Inc. and changed its name to Exponent, Inc. in 1998.

#### CLIENTS

##### General

Exponent serves clients in chemical, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation and other sectors of the economy. Many of our engagements are initiated directly by large corporations or by lawyers or insurance companies whose clients anticipate, or are engaged in, litigation related to their products, equipment, processes or services. The scope of our services in failure prevention and technology evaluation has grown as the technological complexity of products has increased over the years. During fiscal 2018, we provided services representing approximately 27% of revenues to clients in the consumer products industry. During fiscal 2018, we

provided services representing approximately 16% of revenues to clients in the transportation industry. During fiscal 2018, we provided services representing approximately 15% of revenues to clients in the energy and utilities industries. One client accounted for 12% of our revenues during 2018. The same client accounted for 14% of our consolidated revenues for 2017. No client accounted for more than 10% of our consolidated revenues for 2016.

*Pricing and Terms of Engagements*

We provide our services on either a fixed-price basis or on a time and material basis, charging in the latter case hourly rates for each staff member involved in a project, based on his or her skills and experience. Our standard rates for professionals range from \$180 to \$825 per hour. Our engagement agreements typically provide for monthly billing, require payment of our invoices within 30 days of receipt and permit clients to terminate engagements at any time. Clients normally agree to indemnify us and our personnel against liabilities arising out of the use or application of the results of our work or recommendations.

**SERVICES**

Exponent provides high quality engineering and scientific consulting services to clients around the world. Our service offerings are provided on a project-by-project basis. Many projects require support from multiple practices. We currently operate 18 practices in two reportable operating segments, Engineering and Other Scientific and Environmental and Health:

**ENGINEERING AND OTHER SCIENTIFIC**

- Biomechanics
- Biomedical Engineering
- Buildings & Structures
- Civil Engineering
- Construction Consulting



Electrical Engineering & Computer Science

Human Factors  
Industrial Structures  
Materials & Corrosion Engineering  
Mechanical Engineering  
Polymer Science & Materials Chemistry  
Statistical & Data Sciences  
Thermal Sciences  
Vehicle Analysis

## **ENVIRONMENTAL AND HEALTH**

Chemical Regulation & Food Safety  
Ecological & Biological Sciences  
Environmental & Earth Sciences  
Health Sciences

## **ENGINEERING AND OTHER SCIENTIFIC**

### **Biomechanics**

Our Biomechanics Practice uses engineering and biomedical science to solve complex problems at the intersection of biology and engineering. Our expertise is used to understand and evaluate the interaction between the human body as a biological system and the physical environment to explore the cause, nature, and severity of injuries.

During the past year, our biomechanics staff performed analyses of human injuries which occurred while individuals were utilizing a variety of products including recreational vehicles, sporting goods, trucks, trains, aircraft, industrial equipment, and automobiles. They also looked at the implications of using protective devices (such as restraint systems, airbags, and helmets) on reducing the potential for injury, and assessed injuries in the workplace, in the home, and during recreational activities. Our consultants also evaluated product designs for performance, hazards, and injury risks to assist clients with design modifications, address consumer feedback, and respond to regulators.

### **Biomedical Engineering**

Our Biomedical Engineering Practice applies engineering principles to medical technologies, including the evaluation of designs and performance of medical devices, pharmaceuticals, and biologics. Our engineers and scientists assist clients with characterization of biomaterials, medical devices, and their interactions with pharmaceuticals, cells, and tissues. To assist in regulatory clearance and approval, we perform preclinical testing, help formulate related regulatory strategy, and conduct design verification and validation. We also assist with design and manufacturing failure analyses, recall management, and medical device explant analysis. In addition, our staff performs analysis of clinical outcomes for medical devices and related procedures using administrative claims databases. Our expertise is also utilized in product liability, intellectual property litigation, technology acquisition and due diligence matters.

## **Buildings & Structures**

The basic function of a building is to provide structurally sound, durable and environmentally controlled space to house and protect occupants and contents. If this basic function is not achieved, it is because one or more aspect(s) of the building design or construction failed to perform its intended function. Our architects, structural engineers, and material scientists have been investigating such failures for decades, and we use this experience to solve problems with building systems and components, including finding the best repair options and mitigating the risk of future failures.

During the past year, we have evaluated numerous problems with residential, commercial and industrial structures for owners, designers, and builders. Our evaluations often include property inspections, laboratory or on site testing, engineering analysis, and the development of repair recommendations. In addition, we have worked with owners to assess and mitigate the risk of failure associated with hazards such as hurricanes, earthquakes, tsunamis and aging infrastructure. We have assessed these risks to high-rise buildings, industrial facilities, pipelines and nuclear power plant structures.

## **Civil Engineering**

Our Civil Engineering Practice provides broad expertise that includes geotechnical engineering, geological engineering, engineering geology, and geology to address a host of geo-failures, including landslides, foundation and retaining wall failures, pipeline failures, dam and levee failures, and construction claims. We also provide peer review services for complicated structures. Over the past year, our consultants have been engaged in a number of investigations related to wildland fires, debris flows, landslides, retaining wall, reinforced earth slope and foundation failures, large construction claims, flooding and sediment transport. This practice provided services for property owners, contractors, design professionals, attorneys and insurance carriers.

## **Construction Consulting**

Our Construction Consulting Practice provides expertise in the areas of project advisory, risk analysis, strategic planning, dispute resolution, delay analysis and financial damages. During the past year, we expanded the practice by leveraging key client relationships in several construction sectors including utilities, infrastructure and oil and gas. The practice has been retained on numerous complex international arbitrations in Asia Pacific, Europe and the Middle East. Our multi-disciplinary staff, which includes engineers, project managers, schedulers, quantity surveyors, and financial specialists, provides these services to both the public and private sectors for clients who represent a diverse mix of corporations, law firms and agencies. Our projects include many sectors of the construction and engineering industry which include power plants, electric and gas utilities, petrochemical facilities, transportation systems, tunnels, airports, and sporting arenas.

## **Electrical Engineering & Computer Science**

Our Electrical Engineering and Computer Science Practice offers a broad range of expertise to address complex issues for industrial, government and private clients. Our power engineers advise and offer guidance to clients on problems relating to electrical systems including power generation, transmission and distribution. Our team of electrical engineers works on failure analysis, product robustness and reliability for consumer and industrial electronics. Our computer engineers and scientists work with high-tech industries and computer controlled applications to evaluate product safety and software reliability. The computer engineering and science expertise we offer encompasses a breadth of areas including information and numerical sciences, algorithms and data structures, computer graphics, computer architecture, networking and communications, as well as security and cryptography. We operate laboratories for testing heavy equipment and electronics and we have a broad capability in analyzing computer software.

Over the past year, we performed a wide array of investigations ranging from assessing electrical damage to infrastructure from the effect of weather related events to working with clients to develop sophisticated machine learning algorithms applied to large quantities of unstructured data. We continue to work with consumer electronics manufacturers and the transportation industry on the reliability and robustness of computer controlled equipment for user safety.

## **Human Factors**

Our Human Factors Practice evaluates human performance and safety in product and system use. Our consultants study how the limitations and capabilities of people, including memory, perception, attention, reaction time, judgment, physical size and dexterity, affect the way they use a product, interact with an organization or environment, process

information or participate in an activity.

We review warnings and labeling issues related to consumer products, pharmaceuticals, motor vehicles, medical devices and industrial products – supporting the development of safety information to accompany products and assessing claims that the safety information provided was inadequate. We apply our expertise in human behavior, warnings, and decision making in class actions suits, and in evaluating claims seeking to establish a class. In addition, we assist manufacturers with compliance with regulatory guidelines related to products and work with them regarding analysis of adverse event reports and consumer complaints in publicly available databases overseen by the Consumer Product Safety Commission and the Food and Drug Administration.

We examine the role that attention plays in human perception, memory, and behavior, and how attention, inattention, and distraction may affect safety in a wide range of settings and activities (e.g., operating vehicles and machinery, walking, and using consumer products). We address the reliability of human memory and retrospective reporting in the gathering of fact-based evidence. We utilize scientific investigations and research (e.g., human perception, reaction time, and looking behavior) to assess driver behavior in both accident investigations and during the design of automotive systems. Exponent's Human Factors scientists have been actively engaged in research and project work with Advanced Driver Assistive System (ADAS) and automated vehicle technology, in order to understand and advise our clients on how these technologies may change the nature and dynamic of driving, and the role and performance of the driver.

We provide user experience research, including focus groups, usability testing, and complex user studies with custom-tailored designs, across a wide range of industries, including consumer electronics, medical devices, and vehicle technologies. Our state-of-the-art Phoenix User Research Center, with 5,000 square feet of research space, has six lab suites, including a dedicated focus group room, an ophthalmological lab, a motion capture lab, and wearable eye tracking technology, plus connectivity to our vehicle test track. The scope of human factors engagements range from consulting on our clients' research to providing turnkey research solutions.

We perform incident investigations and root cause analyses of near-misses and accidents involving human error in occupational and industrial settings. Our Human Factors scientists have advanced technical systems training and experience required to understand how humans contribute to the initiation of, and emergency response to, explosions, fires, chemical releases, and major equipment failures in the manufacturing, utility, oil and gas, and construction industries, among others. We also capitalize on this knowledge to conduct human error risk and culture assessments to help clients proactively control human performance gaps, improve occupational and process safety performance, and create administrative controls and procedures. In addition to helping clients address the frequency and severity of incidents related to human error, fatigue, and performance, these and other similar project activities can be leveraged to improve efficiency, reliability, and maintainability of normal operations.

## **Industrial Structures**

Our Industrial Structures Practice, based in Düsseldorf, Germany with offices in Hamburg and Berlin, provides specialized engineering expertise required for industrial structures subject to extreme conditions. We have provided planning, condition assessment, rehabilitation design, failure analysis and engineered demolition and dismantling for more than 1,000 industrial facilities around the world. Much of our Industrial Structures Practice centers on three types of facilities: antenna masts and towers, power plants, and specialized industrial structures such as refractories to protect against high process temperatures or tanks containing potentially dangerous products. Each year we provide quality assurance, including both inspection and engineering analysis, on almost 1,000 tower structures for a variety of facilities including telecommunications, overhead lines, wind energy, and industrial chimneys. In addition, our consultants provide inspection services to assist our clients with on-time, quality construction on their projects.

We have developed in-house, specialized computer software for non-linear material behavior that can provide realistic performance assessment of a wide variety of specialized structures such as cracked reinforced concrete components, multi-layer refractories and masonry towers. In addition, our staff regularly participates in the creation of consensus engineering standards for assessment and design of industrial facilities.

Our specialized engineers represent our company in the decisive standard committees in Germany and Europe for tower structure, refractory engineering and demolition.

## **Materials & Corrosion Engineering**

Our in-depth knowledge of materials science, corrosion, and metallurgical engineering, combined with the breadth of our collective experience across many industries and disciplines gives our Materials and Corrosion Engineering Practice a unique ability to efficiently provide our clients with solutions to their complex materials-based problems. We use our knowledge and experience to understand how and why materials, products, and processes may not perform their intended function, as well as to prevent future problems. In the past year, our Materials and Corrosion Engineering Practice helped clients solve critical materials-related issues in the consumer electronics, medical device, battery systems, chemical processing, transportation, energy, utilities, and aerospace fields, among others. The Materials and Corrosion Engineering Practice continues to expand its presence in Asia with hires in our Shanghai and Hong Kong offices.

## **Mechanical Engineering**

We provide clients with a thorough comprehension of current and alternative designs of mechanical systems to identify vulnerabilities before failures occur, develop appropriate risk mitigation methods, and provide post-failure investigations. Our consultants review the performance and reliability of industrial processes, manufactured products, and engineered systems, and we determine the root cause of failures. We assist in legal and insurance matters, failure investigations, product recall investigations, internal compliance programs, product development, workplace safety evaluations, and intellectual property matters.

Our staff members develop and utilize detailed and validated computational models and laboratory experimental methods to evaluate products, systems, and equipment. We perform field inspections, rely on industry standards, and utilize operational data to inform our analyses. We have performed these activities in a broad range of industries including transportation, heavy equipment, building systems, medical devices, energy, and consumer products. During the past year, our mechanical engineers worked on a wide variety of projects ranging from high-profile consumer product recall investigations to industrial equipment failures and mechanical safety issues.

### **Polymer Science & Materials Chemistry**

Our Polymer Science and Materials Chemistry Practice consults with industrial, government, legal, insurance and individual clients regarding polymers and textiles used in diverse applications as well as the chemistry, materials and processing aspects of batteries, drug delivery systems, and other products that depend on highly controlled manufacturing environments. We assist clients in understanding the short- and long-term performance of plastic, rubber, adhesive, coating, composite, reactive chemical systems, and electrochemical energy storage systems when challenged by physical, chemical, thermal and other operational stressors. Our work also includes customized chemical, electrochemical and rheological testing and leverages expanding internal infrastructure for instrumented analysis and advanced imaging capabilities.

Our consultants participate in product development programs, perform failure analyses and provide support to clients involved in regulatory and legal proceedings and the protection of intellectual property. Clients value our technical expertise related to chemistry, formulation, manufacturing and materials performance, our understanding of the history and evolution of these materials, and our ability to assist them in identifying and incorporating emerging materials and manufacturing technologies into their businesses. During the past year, significant program activities addressed aspects of battery systems, consumer electronics, wearable devices, implantable medical devices, drug delivery systems, medical diagnostics, building materials, water handling systems, synthetic turf, the plastics supply chain, fire retardancy and flammability, technology scouting, materials science aspects of health risk, service life prediction, sustainability, and intellectual property related to consumer, recreational, medical, pharmaceutical, food packaging and other products, including trade secrets.

### **Statistical & Data Sciences**

The Statistical and Data Sciences Practice comprises our core capabilities in methods for the collection, management, visualization, and inferential analysis of data. Drawing on experience in a breadth of engineering, science, health, and environmental applications—and frequently working in collaboration with other practices—we assist clients at all stages of the product or process life cycle: designing and analyzing product development studies; improving and controlling manufacturing process and product quality; and monitoring the safety, reliability, and performance of products in use by customers. We design sample surveys and experiments, create value-added databases through synthesis of

client-supplied and public data, and implement innovative techniques for machine learning and predictive analytics. Our approach to studies is intended to support data-driven decision making and to help clients measure their risks and benefits to determine appropriate courses of action.

During the past year, our statisticians and data scientists worked on diverse projects for government, industry, and legal clients. We performed assessments of manufacturing quality systems, evaluated the durability and reliability of smart cards for identity management and credentialing, advised on development and safety-related testing of an automated vehicle control system, examined the in-service reliability of home appliances and components, and provided statistical analysis of clinical data supporting the regulatory submission for a medical device.

### **Thermal Sciences**

Our Thermal Sciences Practice provides multi-disciplinary expertise to assist clients in chemical, fire protection, and mechanical engineering. We have investigated and analyzed thousands of fires and explosions ranging from high loss disasters at manufacturing facilities, energy facilities and oil and gas installations to small insurance claims. Information gained from these analyses has helped us assist clients with preventive measures related to the design of their facilities and products. We assist clients in minimizing the risk of fires and explosions, we provide regulatory consulting for permitting new industrial facilities, and we assist manufacturers in addressing the risk of fires associated with consumer products. Our engineers use fire modeling and other computational fluid dynamics modeling tools to supplement our analytical, experimental, and field-based activities. Preventive services include process safety hazard analysis for the chemical and oil and gas industries, fire protection engineering and dust explosion consulting.



In recent years, the Thermal Sciences Practice has developed tools to evaluate fire and explosion risks of lithium-ion batteries. We have consulted with a variety of clients to evaluate and mitigate fire and explosion hazards of batteries in applications including consumer products, vehicles and energy storage.

During the past year, our work in oil and gas exploration and production, Liquefied Natural Gas (LNG) and downstream oil and gas sectors has continued. Our services in these areas include assessing new oil well control technologies, assessing potential fire and explosion risks and consequences, investigating loss of containment incidents and assessing the integrity of fixed assets.

### **Vehicle Analysis**

We have performed thousands of investigations for the automotive, trucking, recreational vehicle, marine, aerospace, and rail industries. Internal research programs and client projects have resulted in technological contributions that have assisted manufacturers in the understanding of product performance and provided insight to government agencies in establishing policy and regulations. Information gained from these analyses has also assisted clients in assessing preventive measures related to the design of their products, as well as evaluating failures.

Our Test and Engineering Center located in Phoenix, Arizona, is used for our most complex testing and analysis. We have gained a worldwide reputation for our ability to mobilize resources expeditiously and efficiently, integrate a broad array of technical disciplines, and provide valuable insight that is objective and withstands rigorous scrutiny. Many of our projects involve addressing the cause of accidents and our clients rely on us to determine what happened in an accident and why it happened. In many cases, clients also want us to assess what could have been done to reduce the severity of the accident or to mitigate occupant injuries to those involved. Current advances in emerging transportation technologies and concepts allow our multi-disciplinary team of scientists, engineers, and analysts across numerous practices to focus on the development and implementation of connected vehicles, automated vehicles, connected/smart cities, and data analyses. Whether the objective is design analysis, component testing, failure analysis, or accident reconstruction, our knowledge of vehicle systems and engineering principles coupled with our experience from conducting full-scale tests aim to add insight and proficiency to every project.

## **ENVIRONMENTAL AND HEALTH SCIENCES**

### **Chemical Regulation & Food Safety**

Our Chemical Regulation and Food Safety Practice includes both technical and regulatory specialists who are experienced in dealing with foods, food ingredients, cosmetics, dietary supplements, pesticide and biocides (including conventional chemicals, biochemicals, microbials, antimicrobials/biocides, and products of biotechnology), and industrial chemicals. We provide practical, scientific and regulatory support to meet global business objectives at every stage of the product cycle, from research and development to retail and beyond.

During the past year, our Chemical Regulation and Food Safety staff have conducted a wide array of work. The European and U.S. sides of the practice were jointly involved with the ongoing support of multiple new pesticide active ingredients and end-use products. The European side of our business was involved with many projects related to plant protection and biocidal product regulatory submissions, from new active substances and those under review to product-specific dossiers for European member states. In addition, we provided many specialist assessments relating to human and environmental exposure and product efficacy as well as national and international Maximum Residue Limit/import tolerance submissions covering countries such as South Korea, Taiwan and Hong Kong. In Europe and the U.S., we continued to provide clients with regulatory compliance support for food contact materials, food additives, novel foods, nutrition-related analyses, as well as undertaking safety assessments for food and cosmetics products. We also provided proactive and reactive product safety and litigation support. For industrial chemicals, we continued to provide full regulatory support for our clients who prepared and submitted registrations and risk assessments. Our European Offices were particularly active in the first half of the year helping our clients with their EU REACH regulatory requirements for the 2018 deadline and also providing post submission support, dealing with regulatory evaluations and decisions. In the U.S. we continued to provide services related to new pesticide active ingredients and end-use product development and registrations in the U.S., Canada, and Mexico, registration review under EPA, import tolerances in the U.S. and Canada, due diligence related to product and/or business sales, and data compensation, as well as the approval of new pesticide inert ingredients and new non-pesticide active ingredient approvals.

## **Ecological & Biological Sciences**

Our ecological and biological scientists provide strategic support on issues related to natural resources damages associated with chemicals and forest fires, international environmental disputes, ecosystem service assessments for businesses, adverse weather events/climate change, ecological risk assessment, ecotoxicology, novel remediation methods, restoration of wetlands and other natural resources, large development projects, resource utilization (such as mineral mining, oil and gas, wood pulp, etc.), agriculture land-use impacts, genomic assessments, and the use of chemicals and other products in commerce. The practice specializes in assessing the integrated effects of chemical, biological, and physical stressors on aquatic and terrestrial ecosystems. Many of these assessments utilize a causal analysis approach to systematically and transparently determine causation in complex and interrelated situations. The practice is comprised of nationally recognized experts that cover disciplines related to the ecological implications and risks associated with these projects.

## **Environmental & Earth Sciences**

Our environmental scientists and engineers provide cost-effective, scientifically defensible and realistic assessments and solutions to complex environmental issues. We offer technical, regulatory, and litigation support to industries that include oil and gas, mining and minerals, chemicals, forest products, railroads, aerospace, development, and trade associations, and to municipal and governmental clients. Our consultants specialize in the areas of environmental fate and transport, environmental chemistry and forensics, hydrogeology, modeling and monitoring, water quality, water rights and water resources, natural resource damage assessments, data analytics, remediation consulting, environmental engineering and waste management, extreme weather event risk management, and evaluation of environmental and social risks. Our work typically involves complex and high visibility environmental problems and issues, often the focus of environmental or toxic tort claims, where evaluation of contamination, historical reconstruction of events, releases, and doses are central to problem resolution. We provide case-specific strategic and advisory consulting on risk mitigation, planning, and environmental regulatory and policy issues, as well as high-level technical strategic consulting for complex matters where understanding the long-term implications of early technical actions is critical to managing overall liability.

## **Health Sciences**

Our health scientists, including epidemiologists, toxicologists, industrial hygienists, exposure scientists, air quality scientists, biostatisticians, risk assessment scientists, and physicians, apply scientific and medical principles to examine and address complex human-health-related risk issues in a variety of settings. Our consultants are recognized nationally and internationally for our outstanding expertise and credentials, and our decades of experience in government, academia, and industry sectors. Our work has included numerous community and environmental health assessments, disease cluster investigations, air quality investigations and analyses, survey research, cohort and

case-control studies, exposure assessment and simulation studies, biologically-based modeling, meta-analyses, and state-of-the-art literature reviews. We have addressed critical issues for clients on industrial chemicals, pesticides, mineral fibers, drugs, medical devices, consumer products, nanotechnology, and other agents and products as they relate to human health risk.

Our multidisciplinary team has extensive experience investigating a broad variety of health concerns such as claims of adverse health effects from exposures to a wide range of physical agents (e.g., ionizing radiation, low- and radio-frequency electromagnetic fields); chemical agents (e.g., volatile organic compounds, metals, dusts, air pollutants, mineral fibers, fumes, nanoparticles, and pharmaceuticals); and biological agents (fungi/molds, bacteria, and other micro-organisms). We can assess the potential health effects of occupational and environmental exposures; investigate accidental releases of chemicals and evaluate fate and transport of chemical substances; characterize consumer and workplace exposures through simulation and exposure reconstruction; provide air quality and meteorological modeling, permitting, and licensing support services; develop measures of prevention and exposure control; and assist clients with occupational safety and health evaluations and emergency preparedness and response.

## COMPETITION

The marketplace for our services is fragmented and we face different sources of competition in providing various services. In addition, the services that we provide to some of our clients can be performed in-house by those clients. Clients that have the capability to perform such services themselves will retain Exponent or other independent consultants because of independence concerns.

In each of our practices, we believe that the principal competitive factors are: technical capability and breadth of services, ability to deliver services on a timely basis, professional reputation and knowledge of litigation and regulatory processes. Although we believe that we generally compete favorably in each of these areas, some of our competitors may be able to provide services acceptable to our clients at lower prices.

We believe that the barriers to entry are low and that for many of our technical disciplines, competition is increasing. In response to competitive forces in the marketplace, we continue to look for new markets for our various technical disciplines.

## EMPLOYEES

As of December 28, 2018, we employed 1,122 full-time, part-time and hourly employees, including 886 engineering and scientific staff, 72 technical support staff and 164 administrative and support staff. Our staff includes 794 employees with advanced degrees, of which 584 employees have achieved the level of Ph.D., Sc.D. or M.D.

## ADDITIONAL INFORMATION

The address of our Internet website is [www.exponent.com](http://www.exponent.com). We make available, free of charge through our website, access to our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other periodic and current Securities and Exchange Commission (SEC) reports, along with amendments to all of those reports, as soon as reasonably practicable after we file or furnish the reports with the SEC. Copies of material filed or furnished by us with the SEC may also be obtained by writing to us at our corporate headquarters, Exponent, Inc., Attention: Investor Relations, 149 Commonwealth Drive, Menlo Park, CA 94025, or by calling (650) 326-9400. The content of our Internet website is not incorporated into and is not part of this Annual Report on Form 10-K.



**EXECUTIVE OFFICERS OF THE REGISTRANT**

The executive officers of Exponent and their ages as of February 22, 2019 are as follows:

| <u>Name</u>                    | <u>Age</u> | <u>Position</u>   |
|--------------------------------|------------|---|
| Paul R. Johnston, Ph.D.        | 65         | Executive Chairman of the Board of Directors                              |
| Catherine Ford Corrigan, Ph.D. | 50         | President and Chief Executive Officer                                     |
| Robert I. Haddad, Ph.D.        | 61         | Group Vice President  |
| Harri K. Kytomaa, Ph.D.        | 60         | Group Vice President  |
| Steven J. Murray, Ph.D.        | 44         | Group Vice President  |
| John D. Osteraas, Ph.D.        | 64         | Group Vice President  |
| John D. Pye, Ph.D.             | 48         | Group Vice President  |
| Richard Reiss, Sc.D.           | 52         | Group Vice President  |
| Richard L. Schlenker, Jr.      | 53         | Executive Vice President, Chief Financial Officer and Corporate Secretary |
| Sally B. Shepard               | 58         | Chief Human Resources Officer   |

Executive officers of Exponent are appointed by the Board of Directors and serve at the discretion of the Board or until the appointment of their successors. There is no family relationship between any of the directors and officers of the Company.

**Paul R. Johnston, Ph.D.**, joined the Company in 1981, was promoted to Principal Engineer in 1987, and to Vice President in 1996. In 1997, he assumed responsibility for the firm's network of offices. In 2003 he was appointed Chief Operating Officer and added responsibility for the Health and Environmental Groups. In 2006, he assumed line responsibility for all of the firm's consulting groups. Dr. Johnston was named President in May 2007. He was named Chief Executive Officer and elected to the Board of Directors in May 2009. Dr. Johnston was appointed Executive Chairman of the Board of Directors in May 2018. Dr. Johnston received his Ph.D. (1981) in Civil Engineering and M.S. (1977) in Structural Engineering from Stanford University. He received his B.A.I. (1976) in Civil Engineering with First Class Honors from Trinity College, University of Dublin, Ireland where he was elected a Foundation

Scholar in 1975. Dr. Johnston is a Registered Professional Civil Engineer in the State of California and a Chartered Engineer in Ireland.

**Catherine Ford Corrigan, Ph.D.**, joined the Company in 1996. She was promoted to Principal in the Biomechanics practice in 2002 and was appointed Group Vice President in May 2012. Dr. Corrigan was named President in July 2016. She was named Chief Executive Officer and elected to the Board of Directors in May 2018. Dr. Corrigan earned her Ph.D. (1996) in Medical Engineering and Medical Physics and M.S. (1992) in Mechanical Engineering from the Massachusetts Institute of Technology and her B.S. in Bioengineering from the University of Pennsylvania. Prior to joining Exponent, Dr. Corrigan was a researcher in the Orthopaedic Biomechanics Laboratory at Beth Israel Hospital and Harvard Medical School.

Robert I. Haddad, Ph.D., joined the Company in May 2016 as a Corporate Vice President and Principal Scientist. He was promoted to Group Vice President in October 2016. Prior to joining the Company, Dr. Haddad was Chief, Assessment & Restoration Division, Office of Response & Restoration at the National Oceanic and Atmospheric Administration from 2007 to 2016 where he was responsible for the strategic evaluation and tactical resolution of environmental problems. From 2002 to 2007, Dr. Haddad was President and Principal Scientist at Applied Geochemical Strategies, Inc. where he was responsible for providing litigation support and expertise in environmental forensics, human health and ecological risk assessments, and natural resource damage assessments to regional, national, and international clients. Dr. Haddad received his Ph.D. (1989) in Chemical Oceanography from the University of North Carolina, Chapel Hill and B.S. (1979) in Geology from the University of California, Los Angeles. Dr. Haddad has published in peer-reviewed technical publications and scientific journals, and has authored over 300 technical reports and confidential documents for a variety of projects.



Harri K. Kytomaa, Ph.D., joined the Company in 1994. He was promoted to Principal Engineer in 1999 and was appointed Corporate Vice President in 2006. Dr. Kytomaa was appointed Group Vice President in October 2016. Dr. Kytomaa received his Ph.D. (1986) in Mechanical Engineering and M.S. (1981) in Mechanical Engineering from the California Institute of Technology, and B.Sc. (1979) in Engineering Science from Durham University, England. He is a Registered Professional Engineer in 9 states and a Certified Fire and Explosion Investigator in accordance with the National Association of Fire Investigators National Certification Board. Prior to joining Exponent, Dr. Kytomaa was Assistant Professor and Associate Professor of Mechanical Engineering at the Massachusetts Institute of Technology, where he was head of the Fluid Mechanics Laboratory.

Steven J. Murray, Ph.D., joined the Company in 2001. He was promoted to Principal Engineer in 2008. Dr. Murray was promoted to Corporate Vice President in May 2014 and Group Vice President in January 2015. Dr. Murray received his Ph.D. (2000) in Materials Science and Engineering (Electronic Materials Panel) from the Massachusetts Institute of Technology, B.S. (1996) in Materials Science and Mineral Engineering and B.S. (1996) in Mechanical Engineering from the University of California, Berkeley. He is a Registered Professional Electrical Engineer in the State of Oregon and Registered Professional Mechanical Engineer in the State of California.

**John D. Oстераas, Ph.D.**, worked for the Company from 1982 to 1985 as a Senior Engineer. He rejoined the Company in 1990 as a Managing Engineer. He was promoted to Principal Engineer in 1992 and Group Vice President in 2006. Dr. Oстераas received his Ph.D. (1990) in Civil Engineering from Stanford University, M.S. (1977) in Civil Engineering: Structural Engineering from Stanford University and B.S. (1976) in Civil and Environmental Engineering from the University of Wisconsin. Dr. Oстераas is a Registered Professional Engineer in 19 states and is a Fellow of the American Society of Civil Engineers.

John D. Pye, Ph.D., joined the Company in 1999. He was promoted to Principal Engineer in 2006 and was appointed Corporate Vice President in 2009. Dr. Pye was appointed Group Vice President in January 2014. Dr. Pye received his Ph.D. (1999) in Aerospace Engineering from Stanford University, M.S. (1993) in Aerospace Engineering from Stanford University, and B.A.Sc. (1992) in Engineering Science from the University of Toronto, Canada. He is a Registered Professional Mechanical Engineer in the State of California. Prior to joining Exponent, Dr. Pye held a research position in the Aerospace Fluid Mechanics Lab at Stanford University where he was responsible for the renovation and redesign of the Stanford Low-Speed wind tunnel as well as managing the Stanford experimental facilities for the Stanford/NASA Ames Joint Institute for Aeronautics and Astronautics.

**Richard Reiss, Sc.D.**, joined the Company in 2006 as a Principal Scientist. He was promoted to Group Vice President in January 2015. Dr. Reiss earned his Sc.D. (1994) in Environmental Health from the Harvard University School of Public Health, M.S. (1991) in Environmental Engineering from Northwestern University and B.S. (1989) in Chemical Engineering from the University of California, Santa Barbara. Prior to joining Exponent he was a Vice President with Sciences International. Dr. Reiss is a Fellow of the Society of Risk Analysis.

Richard L. Schlenker, Jr. joined the Company in 1990. Mr. Schlenker is the Executive Vice President, Chief Financial Officer and Corporate Secretary of the Company. He was appointed Executive Vice President in April 2010, Chief Financial Officer in July 1999 and Secretary of the Company in November 1997. Mr. Schlenker was the Director of Human Resources from 1998 until his appointment as Chief Financial Officer. He was the Manager of Corporate Development from 1996 until 1998. From 1993 to 1996, Mr. Schlenker was a Business Manager, where he managed the business activities for multiple consulting practices within the Company. Prior to 1993, he held several different positions in finance and accounting within the Company. Mr. Schlenker holds a B.S. in Finance from the University of Southern California.

**Sally B. Shepard**, rejoined the Company in 2014 as Vice President - Human Resources and was promoted to Chief Human Resources Officer in 2017. From 2012 to 2014 she served as Vice President Human Resources at 41st Parameter, which was acquired by Experian. From 2002 to 2009 she served as Vice President Human Resources at CoWare, Inc., which was acquired by Synopsys. From 2000 to 2001 Ms. Shepard served as Vice President Human Resources at Lutris Technologies. She also provided Human Resources consulting services for a variety of companies between roles. From 1981 to 1999 Ms. Shepard held a variety of roles at Exponent including Managing Engineer, Business Manager, Director of Human Resources and Information Technology, and Vice President of Corporate Human Resources. Ms. Shepard holds a B.S. (1982) in Mechanical Engineering from Stanford University.

#### Item 1A. Risk Factors

Exponent operates in a rapidly changing environment that involves a number of uncertainties, some of which are beyond our control and may have a material adverse effect on our financial condition and results of operations. These uncertainties include, but are not limited to, those mentioned elsewhere in this report and those set forth below.

***The unpredictable and reactive nature of our business can create uneven performance in any given quarter or fiscal year.***

Revenues are primarily derived from services provided in response to client requests or events that occur without notice, and engagements, generally billed as services are performed, are terminable or subject to postponement or delay at any time by clients. As a result, backlog at any particular time is small in relation to our quarterly or annual revenues and is not a reliable indicator of revenues for any future periods. Revenues and operating margins for any particular quarter are generally affected by staffing mix, resource requirements and timing and size of engagements.

***Our financial results could suffer if our clients' needs change more rapidly than we are able to secure the appropriate mix of trained, skilled and experienced personnel.***

As our clients' needs change, new technologies develop, and legal and regulatory processes change, we may be unable to timely hire or train personnel with the appropriate new set of skills and experience which could negatively impact our growth and profitability.

***Failure to attract and retain key employees may adversely affect our business.***

Exponent's business involves the delivery of professional services and is labor-intensive. Our success depends in large part upon our ability to attract, retain and motivate highly qualified technical and managerial personnel. Qualified personnel are in great demand and are likely to remain a limited resource for the foreseeable future. We cannot provide any assurance that we can continue to attract sufficient numbers of highly qualified technical and managerial personnel and retain existing employees. We have experienced and expect to continue to experience employee turnover. The loss of key managerial employees, business generators or any significant number of employees could have a material adverse impact on our business, including our ability to secure and complete engagements.

*Competition could reduce our pricing and adversely affect our business.*

The markets for our services are highly competitive. In addition, there are relatively low barriers to entry into our markets and we have faced, and expect to continue to face, additional competition from new entrants into our markets. Competitive pressure could reduce the market acceptance of our services and result in price reductions that could have a material adverse effect on our business, financial condition or results of operations.

*The loss of a large client could adversely affect our business.*

We currently derive a significant portion of our revenues from clients in the chemical, consumer electronics, energy, insurance, transportation and utilities industries. The loss of any large client, organization or insurer could have a material adverse effect on our business, financial condition or results of operations.

*Our clients may be unable to pay for our services.*

If a client's financial difficulties become severe, the client may be unwilling or unable to pay our invoices in the ordinary course of business, which could adversely affect collections of both our accounts receivable and unbilled services. On occasion, some of our clients have entered bankruptcy, which has prevented us from collecting amounts owed to us. The bankruptcy of a client with substantial accounts receivable could have a material adverse effect on our financial condition and results of operations.

On January 29<sup>th</sup> 2019, PG&E Corp. ("PG&E") filed for bankruptcy under chapter 11 of the U.S. bankruptcy code. Our total outstanding accounts receivable from PG&E as of December 28, 2018 was \$5.6 million of which \$2.1 million was paid during fiscal 2019 prior to the bankruptcy filing date. We continued to do work for PG&E during fiscal 2019 and the total outstanding accounts receivable from PG&E on the bankruptcy filing date of January 29, 2019 was \$6.0 million. Due to the uncertainties associated with the bankruptcy process, we believe that an impairment of the receivable is reasonably possible, however we are unable to estimate the amount of this receivable that will ultimately

be collected. As such, we have not recorded an impairment charge related to this asset, but will do so once an impairment, if any, is determined to be probable and estimable.

We hold substantial investments that could present liquidity risks.

Our cash equivalent and short-term investment portfolio as of December 28, 2018, consisted primarily of obligations of U.S. government agencies and the U.S. Treasury. We follow an established investment policy to monitor, manage and limit our exposure to interest rate and credit risk. The policy sets forth credit quality standards and limits our exposure to any one issuer, as well as our maximum exposure to various asset classes.

Investments in some financial instruments may pose risks arising from liquidity and credit concerns. As of December 28, 2018, we had no impairment charge associated with our investment portfolio relating to such adverse financial market conditions. Although we believe our current investment portfolio has a low risk of impairment, we cannot predict future market conditions or market liquidity and can provide no assurance that our investment portfolio will remain unimpaired.

Our business is dependent on our professional reputation.

The professional reputation of Exponent and its consultants is critical to our ability to successfully compete for new client engagements and attract or retain professionals. Proven or unproven allegations against us may damage our professional reputation. Any factors that damage our professional reputation could have a material adverse effect on our business.

Our business can be adversely impacted by deregulation or reduced regulatory enforcement.

Public concern over health, safety and preservation of the environment has resulted in the enactment of a broad range of environmental and/or other laws and regulations by local, state and federal lawmakers and agencies. These laws and the implementation of new regulations affect nearly every industry, as well as the agencies of federal, state and local governments charged with their enforcement. To the extent changes in such laws, regulations and enforcement or other factors significantly reduce the exposures of manufacturers, owners, service providers and others to liability, the demand for our services may be significantly reduced.

*Tort reform can reduce demand for our services.*

Several of our practices have a significant concentration in litigation support consulting services. To the extent tort reform reduces the exposure of manufacturers, owners, service providers and others to liability, the demand for our litigation support consulting services may be significantly reduced.

***Our engagements may result in professional or other liability.***

Our services typically involve difficult engineering and scientific assignments and carry risks of professional and other liability. Many of our engagements involve matters that could have a severe impact on a client's business, cause a client to lose significant amounts of money, or prevent a client from pursuing desirable business opportunities. Accordingly, if a client is dissatisfied with our performance, the client could threaten or bring litigation in order to recover damages or to contest its obligation to pay our fees. Litigation alleging that we performed negligently, disclosed client confidential information, lost or damaged evidence, infringed on patents, were forced to withdraw from a legal matter due to a conflict or otherwise breached our obligations to a client could expose us to significant liabilities to our clients or other third parties or tarnish our reputation.

***Potential conflicts of interest may preclude us from accepting some engagements.***

We provide litigation support consulting and other services primarily in connection with significant disputes, or other matters that are usually adversarial or that involve sensitive client information. The nature of our consulting services has and will continue to preclude us from accepting engagements with other potential clients because of conflicts. Accordingly, the nature of our business limits the number of both potential clients and potential engagements.

***We are subject to unpredictable risks of litigation.***

Although we seek to avoid litigation whenever possible, from time to time we are party to various lawsuits and claims. Disputes may arise, for example, from employment issues, regulatory actions, business acquisitions and real estate and other commercial transactions. There can be no assurances that any lawsuits or claims will be immaterial in the future. Any material lawsuits or claims could adversely affect our business and reputation.

***We are subject to security breaches that may disrupt our operations and/or lead to the inability to protect confidential information.***

We have experienced, and expect to continue to be subjected to, security breaches and threats, none of which have been material to us to date. Despite the implementation of security measures, our operating systems are vulnerable to electronic breaches of security. Such breaches could lead to disruptions of our operations and potential unauthorized disclosure of confidential and/or personal information, which could result in legal claims or proceedings. While we have taken reasonable steps to prevent and mitigate the damage of a security breach by continuously improving our design and coordination of security controls across our business, those steps may not be effective and there can be no assurance that any such steps can be effective against all possible risks.

***Failure to protect client and employee data may have an adverse effect on our business.***

We manage, utilize, and store sensitive or confidential client or employee data, including personal data and protected health information. As a result, we are subject to numerous laws and regulations designed to protect this information, such as the U.S. federal and state laws governing the protection of health or other personally identifiable information, including the Health Insurance Portability and Accountability Act, and international laws such as the European Union General Data Protection Regulation. In addition, many states, U.S. federal governmental authorities and non-U.S. jurisdictions have adopted, proposed, or are considering adopting or proposing, additional data security and/or data privacy statutes or regulations. These laws and regulations are increasing in complexity and number. If any person, including any of our employees, negligently disregards or intentionally breaches our established controls with respect to client or employee data, or otherwise mismanages or misappropriates that data, we could be subject to significant monetary damages, regulatory enforcement actions, fines, and/or criminal prosecution. In addition, unauthorized disclosure of sensitive or confidential client or employee data, whether through systems failure, employee negligence, fraud, or misappropriation, could damage our reputation and cause us to lose clients and their related revenue in the future.

***Impairment of goodwill may require us to record a significant charge to earnings.***

On our balance sheet, we have \$8,607,000 of goodwill subject to periodic evaluation for impairment. Failure to achieve sufficient levels of cash flow at reporting units, the loss of key employees, changes to the scope of operations of our business or a significant and sustained decline in our stock price could result in goodwill impairment charges. During times of financial market volatility, significant judgment is required to determine the underlying cause of the decline and whether stock price declines are short-term in nature or indicative of an event or change in circumstances.



***Impairment of long-lived assets or restructuring activities may require us to record a significant charge to earnings.***

Our long-lived assets, including our office, laboratory and warehouse space in Menlo Park, California, our test and engineering center in Phoenix, Arizona, and our office and laboratory facilities currently under construction in Natick, Massachusetts, are subject to periodic testing for impairment. Failure to achieve sufficient levels of cash flow at the asset group level could result in impairment of our long-lived assets. In addition, we have operating lease commitments for office and laboratory space. Changes in the business environment could lead to changes in the scope of operations of our business. These changes, including the closure of one or more offices, could result in restructuring and/or asset impairment charges.

***Our international operations create special risks that could adversely affect our business.***

In addition to our offices in the United States, we have physical offices in the United Kingdom, Germany, Switzerland, Hong Kong, China and Singapore and conduct business in several other countries. We expect to continue to expand globally and our international revenues may account for an increasing portion of our revenues in the future. Our international operations carry special financial, business and legal risks, including cultural and language differences; employment laws and related factors that could result in lower utilization, higher staffing costs, and cyclical fluctuations of utilization and revenues; currency fluctuations that adversely affect our financial position and operating results; burdensome regulatory requirements and other barriers to conducting business; tariffs and other trade barriers including the United Kingdom's decision to leave the European Union; managing the risks associated with engagements with foreign officials and governmental agencies, including the risks arising from the United States Foreign Corrupt Practices Act and the United Kingdom Bribery Act of 2010; managing the risks associated with global privacy and data security laws and regulations including the General Data Protection Regulation in Europe; greater difficulties in managing and staffing foreign operations; successful entry and execution in new markets; restrictions on the repatriation of earnings; potentially adverse tax consequences; and other impending legislation that could add additional risks to the business.

***Inherent risks related to government contracts may adversely affect our business.***

We work for various United States and foreign governmental entities and agencies. Government entities reserve the right to audit our contracts and conduct inquiries and investigations of our business practices with respect to government contracts. Findings from an audit may result in fees being refunded to the government or prospective adjustment to previously agreed upon rates that will affect future margins. If a government client discovers improper or illegal activities in the course of audits or investigations, we may become subject to various civil and criminal penalties and administrative sanctions, which may include termination of contracts, forfeiture of profits, suspension of payments, fines and suspensions or debarment from doing business with other agencies of the government. The inherent limitations of internal controls may not prevent or detect all improper or illegal activities, regardless of the adequacy of such controls. Government contracts, and the proceedings surrounding them, are often subject to more extensive scrutiny and publicity than other commercial contracts. Negative publicity related to our government contracts, regardless of whether it is accurate, may further damage our business by affecting our ability to compete for new contracts.

***Governments may terminate, cancel, modify or curtail our contracts at any time prior to their completion.***

Under our government contracts, the client generally has the right not to exercise options to extend or expand our contracts and may otherwise terminate, cancel, modify or curtail our contracts at its convenience. Any decision by the client not to exercise contract options or to terminate, cancel, modify or curtail our programs or contracts would adversely affect our revenues, revenue growth and profitability.

***We could incur significant liabilities and suffer negative publicity if people or properties are harmed by the products and systems we sell or the services we offer.***

We, on occasion, design, develop, manufacture, sell, service and maintain various products and systems. In some instances, we also train operators of such products and systems. Many of these products and systems utilize software algorithms that are probabilistic in nature and subject to significant technical limitations. There are many factors, some of which are beyond our control, which could result in the failure of our products or systems. The failure of our products or systems could lead to injury, death, or extensive property damage and may lead to product liability, professional liability, or other claims against us. Further, if our products or systems fail, or are perceived to have failed, the negative publicity from such incident could have a material adverse effect on our business.

***Changes in, or interpretations of, accounting principles could have a significant impact on our financial position and results of operations.***

We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). These principles are subject to interpretation by the SEC and various bodies formed to interpret and create appropriate accounting principles. A change in these principles can have a significant effect on our reported results and may even retroactively affect previously reported transactions. Additionally, the adoption of new or revised accounting principles may require that we make significant changes to our systems, processes and controls.

*Our business can be adversely affected by downturns in the overall economy.*

The markets that we serve are cyclical and subject to general economic conditions. The direction and relative strength of the global economy continues to be uncertain. If economic growth in the United States, where we primarily operate, slows, our clients may consolidate or go out of business and thus demand for our services could be reduced significantly.

*Our quarterly results may vary.*

Variations in our revenues and operating results occur from time to time, as a result of a number of factors, such as the significance of client engagements commenced and completed during a quarter, the timing of engagements, the number of working days in a quarter, employee hiring and utilization rates, and integration of companies acquired. Because a high percentage of our expenses, particularly personnel and facilities related expenses, are relatively fixed in advance of any particular quarter, a variation in the timing of the initiation or the completion of our client assignments can cause significant variations in operating results from quarter to quarter.

*The market price of our common stock may be volatile.*

Many factors could cause the market price of our common stock to rise and fall. These include the risk factors listed above and below; changes in estimates of our performance or recommendations by securities analysts; future sales of shares of common stock in the public market; market conditions in the industry and economy as a whole; acquisitions or strategic alliances involving us or our competitors; restatement of financial results; and changes in accounting principles or methods. In addition, the stock market often experiences significant price fluctuations. These fluctuations are often unrelated to the operating performance of particular companies. These broad market fluctuations may adversely affect the market price of our common stock. When the market price of a company's stock drops significantly, shareholders often institute securities class action litigation against that company. Any litigation against us could cause us to incur substantial costs, divert the time and attention of our management and other resources, or otherwise harm our business.

*There can be no assurance that we will continue to declare cash dividends or repurchase our shares at all or in any particular amounts.*

Our Board of Directors has declared quarterly dividends since March 2013. Our intent to continue to pay quarterly dividends and to repurchase our shares is subject to capital availability and, in the case of dividends, periodic determinations by our Board of Directors that cash dividends are in the best interest of our stockholders and are in compliance with all laws and agreements applicable to the declaration and payment of cash dividends by us. Future dividends and share repurchases may also be affected by, among other factors: our views on potential future capital requirements for investments, including acquisitions; legal risks; stock repurchase programs; changes in federal and state income tax laws or corporate laws; contractual restrictions; and changes to our business model. Our dividend payments and share repurchases may change from time to time, and we cannot provide assurance that we will continue to declare dividends or repurchase shares at all or in any particular amounts. A reduction or suspension in our dividend payments or share repurchase activity could have a negative effect on our stock price.

Item 1B. Unresolved Staff Comments

None.

Item 2. Properties

Our Silicon Valley office facilities consist of a 153,738 square foot building, with office and laboratory space located on a 6.3-acre tract of land we own in Menlo Park, California and an adjacent 27,000 square feet of warehouse storage space on a 1.1-acre tract of land that we also own.

Our Test and Engineering Center (TEC) occupies 147 acres in Phoenix, Arizona. We lease this land from the state of Arizona under a 30-year lease agreement that expires in January 2028 and have options to renew for two fifteen-year periods. We constructed a 21,613 square foot indoor test facility as well as a 44,053 square foot engineering and test preparation building at the TEC.

During the first quarter of 2018, we closed on the purchase of 2.9 acres of land in Natick, Massachusetts on which we are constructing a 60,480 square foot building with office and laboratory facilities.

In addition, we lease office and laboratory space in 21 other locations in 13 states and the District of Columbia, as well as in Germany, China, Hong Kong, Singapore, Switzerland and the United Kingdom. Leases for these offices and laboratory facilities have terms generally ranging between one and ten years. Aggregate lease expense in fiscal 2018 for all leased properties was \$7,488,000.

Item 3. Legal Proceedings

Exponent is not engaged in any material legal proceedings.

Item 4. Mine Safety Disclosures

Not applicable.

PART II

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Exponent's common stock is traded on the NASDAQ Global Select Market, under the symbol "EXPO."

As of February 15, 2019, there were 175 holders of record of our common stock. Because many of the shares of our common stock are held by brokers and other institutions on behalf of stockholders, we believe that there are considerably more beneficial holders of our common stock than record holders.

The following table provides information on the Company's share repurchases (of Company common stock) for the quarter ended December 28, 2018 (in thousands, except price per share):

|                            | Total Number<br>of Shares<br>Purchased | Average<br>Price Paid<br>Per Share | Total Number of<br>Shares Purchased<br>as Part of Publicly<br>Announced Plans<br>or Programs | Approximate Dollar<br>Value of Shares That<br>May Yet Be Purchased<br>Under the Plan or<br>Program |
|----------------------------|--|------------------------------------|--|--|
| September 29 to October 26 | 40                                     | \$ 49.14                           | 40   | \$ 43,411  |
| October 27 to November 23  | 214                                    | \$ 50.88                           | 214  | \$ 32,488  |
| November 24 to December 28 | 308                                    | \$ 48.83                           | 308  | \$ 17,462  |
| Total                      | 562                                    | \$ 49.63                           | 562  |  |

Repurchases of the Company's common stock were effected pursuant to a repurchase program authorized by the Company's Board of Directors. On October 21, 2015, the Company's Board of Directors announced \$35,000,000 for the repurchase of the Company's common stock. On October 19, 2016, the Company's Board of Directors announced \$35,000,000 for the repurchase of the Company's common stock. On January 31, 2019, the Company's Board of Directors announced \$75,000,000 for the repurchase of the Company's common stock. These repurchase programs have no expiration dates.

#### COMPANY STOCK PRICE PERFORMANCE GRAPH

The graph compares the Company's cumulative total stockholder return calculated on a dividend-reinvested basis from 2013 through 2018 with those of the Standard & Poor's ("S&P") 500 Index and the S&P SmallCap 600 Index. The Company does not have a comparable peer group and thus has selected the S&P Small Cap 600 Index. The graph assumes that \$100 was invested on the last day of 2013. Note that the historic stock price performance is not necessarily indicative of future stock price performance.

**Item 6. Selected Financial Data**

The following selected consolidated financial data are derived from our consolidated financial statements. This data should be read in conjunction with the consolidated financial statements and notes thereto, and with *Part II - "Item 7: Management's Discussion and Analysis of Financial Condition and Results of Operations."*

| (In thousands, except per share data)          | Fiscal Year |           |           |           |           |
|--|-------------|-----------|-----------|-----------|-----------|
|  | 2018        | 2017      | 2016      | 2015      | 2014      |
| <b>Consolidated Statements of Income Data:</b> |             |           |           |           |           |
| Revenues before reimbursements                 | \$354,639   | \$329,664 | \$299,197 | \$295,705 | \$289,209 |
| Revenues                                       | \$379,523   | \$347,799 | \$315,076 | \$312,832 | \$304,704 |
| Operating income                               | \$91,456    | \$72,051  | \$61,911  | \$68,933  | \$63,549  |
| Net income                                     | \$72,254    | \$41,305  | \$47,480  | \$43,599  | \$40,701  |
| Net income per share:                          |             |           |           |           |           |
| Basic  | \$1.37      | \$0.78    | \$0.90    | \$0.82    | \$0.76    |
| Diluted  | \$1.33      | \$0.77    | \$0.87    | \$0.80    | \$0.74    |
| Cash dividends declared per share              | \$0.52      | \$0.42    | \$0.36    | \$0.30    | \$0.25    |
| <b>Consolidated Balance Sheet Data:</b>        |             |           |           |           |           |
| Cash and cash equivalents                      | \$127,059   | \$124,794 | \$114,967 | \$125,751 | \$129,490 |
| Short-term investments                         | \$81,495    | \$71,604  | \$58,755  | \$45,842  | \$24,913  |
| Working capital                                | \$228,308   | \$222,402 | \$193,808 | \$192,312 | \$176,153 |
| Total assets                                   | \$468,936   | \$439,589 | \$403,744 | \$387,507 | \$365,299 |
| Long-term liabilities                          | \$56,723    | \$57,394  | \$50,162  | \$44,229  | \$41,666  |
| Total stockholders' equity                     | \$313,909   | \$289,088 | \$273,346 | \$262,804 | \$244,288 |

**Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations****OVERVIEW**

Exponent is an engineering and scientific consulting firm providing solutions to complex problems. Exponent's interdisciplinary organization of scientists, physicians, engineers, and business consultants draws from more than 90 technical disciplines to solve the most pressing and complicated challenges facing stakeholders today. The firm



leverages over 50 years of experience in analyzing accidents and failures to advise clients as they innovate their technologically complex products and processes, ensure the safety and health of their users, and address the challenges of sustainability.

## **CRITICAL ACCOUNTING ESTIMATES**

In preparing our consolidated financial statements, we make assumptions, judgments and estimates that can have a significant impact on our revenue, operating income and net income, as well as on the value of certain assets and liabilities on our consolidated balance sheet. We base our assumptions, judgments and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. On a regular basis we evaluate our assumptions, judgments and estimates and make changes accordingly. We believe that the assumptions, judgments and estimates involved in accounting for revenue recognition and estimating the allowance for contract losses and doubtful accounts have a potential impact on our consolidated financial statements, so we consider these to be our critical accounting policies. We discuss below the assumptions, judgments and estimates associated with these policies. Historically, our assumptions, judgments and estimates relative to our critical accounting policies have not differed materially from actual results. For further information on our critical accounting policies, see *“Note 1: Summary of Significant Accounting Policies”* of our *Notes to Consolidated Financial Statements*.

**Revenue recognition.** We derive our revenues primarily from professional fees earned on consulting engagements, fees earned for the use of our equipment and facilities, as well as reimbursements for outside direct expenses associated with the services that are billed to our clients.

Substantially all of our engagements are service contracts performed under time and material or fixed-price billing arrangements. For time and material and fixed-price service projects, revenue is generally recognized as the services are performed. For substantially all of our fixed-price service engagements, we recognize revenue based on the relationship of incurred labor hours at standard rates to our estimate of the total labor hours at standard rates we expect to incur over the term of the contract. Our estimate of total labor hours we expect to incur over the term of the contract is based on the nature of the project and our past experience on similar projects. We believe this methodology achieves a reliable measure of the revenue from the consulting services we provide to our customers under fixed-price contracts.

Management judgments and estimates must be made and used in connection with the revenues recognized in any accounting period. These judgments and estimates include an assessment of the estimate as to the total effort required to complete fixed-price projects.

**Estimating the allowance for contract losses and doubtful accounts.** We make estimates of our ability to collect accounts receivable and our unbilled but recognized work-in-process. In circumstances where we are aware of a specific customer's inability to meet its financial obligations to us or for disputes with customers that affect our ability to fully collect our accounts receivable and unbilled work-in-process, we record a specific allowance to reduce the net recognized receivable to the amount we reasonably believe will be collected. For all other customers we recognize allowances for contract losses and doubtful accounts taking into consideration factors such as historical write-offs, customer concentration, customer credit-worthiness, current economic conditions, and aging of amounts due.

The following table sets forth, for the periods indicated, the percentage of revenues of certain items in our consolidated statements of income and the percentage increase (decrease) in the dollar amount of such items year to year:

|                                     | PERCENTAGE OF REVENUES<br>FOR FISCAL YEARS |         |         | PERIOD TO<br>PERIOD CHANGE |               |
|-------------------------------------|--|---------|---------|----------------------------|---------------|
|                                     | 2018                                       | 2017    | 2016    | 2018<br>vs.<br>2017        | 2017 vs. 2016 |
| Revenues                            | 100.0 %                                    | 100.0 % | 100.0 % | 9.1 %                      | 10.4 %        |
| Operating expenses:                 |  |         |         |                            |               |
| Compensation and related expenses   | 56.7                                       | 60.5    | 61.4    | 2.3                        | 8.7           |
| Other operating expenses            | 8.1  | 8.5     | 9.0     | 3.6                        | 4.0           |
| Reimbursable expenses               | 6.6  | 5.2     | 5.0     | 37.2                       | 14.2          |
| General and administrative expenses | 4.6  | 5.1     | 4.9     | (1.4 )                     | 14.8          |
|                                     | 76.0                                       | 79.3    | 80.3    | 4.5                        | 8.9           |
| Operating income                    | 24.0                                       | 20.7    | 19.7    | 26.9                       | 16.4          |
| Other income, net                   | 0.5  | 3.0     | 2.3     | (82.2 )                    | 45.0          |
| Income before income taxes          | 24.5                                       | 23.7    | 22.0    | 13.1                       | 19.4          |
| Provision for income taxes          | 5.5  | 11.8    | 6.9     | (48.9 )                    | 90.4          |
| Net income                          | 19.0 %                                     | 11.9 %  | 15.1 %  | 74.9 %                     | (13.0 %)      |

## EXECUTIVE SUMMARY

Revenues for 2018 increased 9% and revenues before reimbursements increased 8% as compared to the prior year. The increase in revenues before reimbursements was due to an increase in billable hours and an increase in billing rates. We experienced strong demand for our consulting services from a diverse set of clients for both proactive and reactive projects across several industries and geographies. We continue to see demand for our proactive services in the areas of design and regulatory consulting, specifically related to consumer electronics as that industry continues to innovate and face manufacturability challenges. We also continue to see demand for our reactive services from clients in the energy, mining and infrastructure industries with technical and construction management issues on large capital projects. Clients in these industries continue to engage our inter-disciplinary teams to evaluate these claims. We also continue to see demand for our scientists to assess increasing concerns regarding the impact of chemicals on human health and the environment.

During 2018, we had strong growth in our human factors, materials & corrosion engineering, thermal sciences, polymer science & materials chemistry, mechanical engineering, and chemical regulation & food safety practices. We were engaged by clients throughout the year to determine what happened when a disaster occurs. These events range from structural failures on major infrastructure to nanoscale components. During 2018, we completed work on a large human factors assessment for a client in the consumer products industry. This project represented 4% of our revenues before reimbursement during 2018 as compared to 6% during 2017.

Net income increased to \$72,254,000 during 2018 as compared to \$41,305,000 during 2017. Diluted earnings per share increased to \$1.33 for 2018 as compared to \$0.77 for 2017. The increase in net income and diluted earnings per share was partially due to the impact of the U.S. tax legislation that was signed into law during the fourth quarter of 2017. This U.S. tax legislation lowered the U.S. corporate income tax rate from 35% to 21% beginning in 2018, which contributed to the decrease in income tax expense. In addition, we recorded an income tax expense of \$16,507,000 during the fourth quarter of 2017 associated with the tax legislation. We have domestic deferred tax assets primarily associated with our deferred compensation plan and stock-based compensation program, which were previously valued at the federal corporate income tax rate of 35%. Our deferred tax assets were re-measured at the lower enacted corporate tax rate of 21% which contributed \$15,137,000 to the fourth quarter of 2017 income tax expense associated with the tax legislation. We also have foreign earnings that were subject to the mandatory repatriation tax. The total mandatory repatriation tax, net of the benefit of our foreign tax credits, contributed \$1,370,000 to the fourth quarter of 2017 income tax expense associated with the tax legislation.

Income before income taxes increased 13% to \$93,317,000 during 2018 as compared to \$82,509,000 during 2017. We were able to improve pre-tax income by effectively managing headcount to align our resources with demand.

We remain focused on selectively adding top talent and developing the skills necessary to expand upon our market position, providing clients with in-depth scientific research and analysis to determine what happened and how to prevent failures or exposures in the future. We also remain focused on capitalizing on emerging growth areas, managing other operating expenses, generating cash from operations, maintaining a strong balance sheet and undertaking activities such as share repurchases and dividends to enhance shareholder value.

### **OVERVIEW OF THE YEAR ENDED DECEMBER 28, 2018**

Our revenues consist of professional fees earned on consulting engagements, fees for use of our equipment and facilities, and reimbursements for outside direct expenses associated with the services performed that are billed to our clients.

We operate on a 52-53 week fiscal year with each year ending on the Friday closest to December 31<sup>st</sup>. The fiscal years ended December 28, 2018, December 29, 2017 and December 30, 2016 included 52 weeks of activity. Fiscal 2019 is a 53 week fiscal year that will end on Friday, January 3, 2020.

During 2018, billable hours increased 5% to 1,274,000 as compared to 1,218,000 during 2017. Our utilization decreased to 73% for 2018 as compared to 75% for 2017. Technical full-time equivalent employees increased 7% to 839 during 2018 as compared to 784 during 2017 due to our recruiting and retention efforts. We continue to selectively hire key talent to expand our capabilities.

### **FISCAL YEARS ENDED DECEMBER 30, 2018, AND DECEMBER 29, 2017**

#### **Revenues**

| (In thousands except percentages) | Fiscal Years |      | Percent Change |
|-----------------------------------|--------------|------|----------------|
|                                   | 2018         | 2017 |                |

Edgar Filing: EXPONENT INC - Form 10-K

|                                  |           |   |           |   |      |   |
|----------------------------------|-----------|---|-----------|---|------|---|
| Engineering and Other Scientific | \$306,265 |   | \$277,603 |   | 10.3 | % |
| Percentage of total revenues     | 80.7      | % | 79.8      | % |      |   |
| Environmental and Health         | 73,258    |   | 70,196    |   | 4.4  | % |
| Percentage of total revenues     | 19.3      | % | 20.2      | % |      |   |
| Total revenues                   | \$379,523 |   | \$347,799 |   | 9.1  | % |

The increase in revenues for our Engineering and Other Scientific segment was due to an increase in billable hours and an increase in billing rates. During 2018, billable hours for this segment increased by 5.4% to 992,000 as compared to 941,000 during 2017. This segment had strong growth in its human factors, materials & corrosion engineering, thermal sciences, polymer science & materials chemistry and mechanical engineering practices during 2018. We continued to see strong demand for our services related to product recalls including assignments from the consumer products and automotive industries. Proactive services continued to expand as companies seek our interdisciplinary advice throughout the product life cycle, consistent with the increased importance placed on understanding how users interact with complex technologies. Utilization decreased to 75% for 2018 as compared to 77% for 2017. The decrease in utilization was partially due to the completion of a large human factors assessment for a client in the consumer products industry during the third quarter of 2018. This project represented approximately 4% of our revenues before reimbursements during 2018 as compared to 6% during 2017. Technical full-time equivalents increased 8.3% to 640 for 2018 as compared to 591 for 2017 due to our recruiting and retention efforts.

The increase in revenues from our Environmental and Health segment was due to an increase in billable hours and an increase in billing rates. During 2018, billable hours for this segment increased by 1.8% to 282,000 as compared to 277,000 during 2017. The increase in billable hours was due to growth in our chemical regulation and food safety practice where we expanded our proactive services. Utilization decreased to 68% for 2018 as compared to 69% for 2017. The decrease in utilization was partially due to the completion of a large human factors assessment for a client in the consumer products industry during the third quarter of 2018. Technical full-time equivalents increased 3.1% to 199 during 2018 as compared to 193 for 2017 due to our recruiting and retention efforts.

Revenues are primarily derived from services provided in response to client requests or events that occur without notice and engagements are generally terminable or subject to postponement or delay at any time by our clients. As a result, backlog at any particular time is small in relation to our quarterly or annual revenues and is not a reliable indicator of revenues for any future periods.

### Compensation and Related Expenses

| (In thousands except percentages) | Fiscal Years |           | Percent Change |
|-----------------------------------|--------------|-----------|----------------|
|                                   | 2018         | 2017      |                |
| Compensation and related expenses | \$215,052    | \$210,289 | 2.3 %          |
| Percentage of total revenues      | 56.7 %       | 60.5 %    |                |

The increase in compensation and related expenses during 2018 was due to an increase in payroll expense, an increase in fringe benefits, an increase in bonus expense, and an increase in stock-based compensation expense partially offset by a change in the value of assets associated with our deferred compensation plan. During 2018, payroll and fringe benefits increased \$7,188,000 and \$2,043,000, respectively, due to the increase in technical full-time equivalent employees and our annual salary increase. During 2018, bonus expense increased by \$5,107,000 due to a corresponding increase in income before income taxes, before bonus expense, and before stock-based compensation. Stock-based compensation increased \$788,000 due primarily to an increase in the amortization of restricted stock unit grants. During 2018, deferred compensation expense decreased \$10,447,000 with a corresponding decrease to other income as compared with the prior year due to the change in value of assets associated with our deferred compensation plan. This decrease consisted of a decrease in the value of the plan assets of \$3,900,000 during 2018 as compared to an increase in the value of the plan assets of \$6,547,000 during 2017. We expect our compensation expense, excluding the change in value of deferred compensation plan assets, to increase as we selectively add new talent and adjust compensation to market conditions.

### Other Operating Expenses

| (In thousands except percentages) | Fiscal Years |          | Percent Change |
|-----------------------------------|--------------|----------|----------------|
|                                   | 2018         | 2017     |                |
| Other operating Expenses          | \$30,599     | \$29,544 | 3.6 %          |
| Percentage of total revenues      | 8.1 %        | 8.5 %    |                |

Other operating expenses include facilities-related costs, technical materials, computer-related expenses and depreciation and amortization of property, equipment and leasehold improvements. The increase in other operating

## Edgar Filing: EXPONENT INC - Form 10-K

expenses was primarily due to an increase in occupancy expense of \$871,000 due to our increase in technical full-time equivalent employees. We expect other operating expense to grow as we selectively add new talent and make investments in our corporate infrastructure.

### Reimbursable Expenses

| (In thousands except percentages) | Fiscal Years |          | Percent |
|-----------------------------------|--------------|----------|---------|
|                                   | 2018         | 2017     | Change  |
| Reimbursable expenses             | \$24,884     | \$18,135 | 37.2 %  |
| Percentage of total revenues      | 6.6 %        | 5.2 %    |         |

The increase in reimbursable expenses was primarily due to an increase in travel related costs associated with our large human factors assessment project. The amount of reimbursable expenses will vary from year to year depending on the nature of our projects.

### General and Administrative Expenses

| (In thousands except percentages)   | Fiscal Years |          | Percent |
|-------------------------------------|--------------|----------|---------|
|                                     | 2018         | 2017     | Change  |
| General and administrative expenses | \$17,532     | \$17,780 | (1.4 )% |
| Percentage of total revenues        | 4.6 %        | 5.1 %    |         |

The decrease in general and administrative expenses during 2018 was primarily due to a decrease in travel and meals of \$249,000 due to a firm-wide managers meeting during 2017. We expect general and administrative expenses to increase as we selectively add new talent, expand our business development efforts, and pursue staff development initiatives.



## Other Income

| (In thousands except percentages) | Fiscal Years |          | Percent Change |
|-----------------------------------|--------------|----------|----------------|
|                                   | 2018         | 2017     |                |
| Other income                      | \$1,861      | \$10,458 | (82.2 )%       |
| Percentage of total revenues      | 0.5 %        | 3.0 %    |                |

Other income consists primarily of interest income earned on available cash, cash equivalents and short-term investments, changes in the value of assets associated with our deferred compensation plan and rental income from leasing excess space in our Silicon Valley facility. The decrease in other income was primarily due to the change in value of assets associated with our deferred compensation plan partially offset by an increase in interest income. During 2018, other income decreased \$10,447,000 with a corresponding decrease to deferred compensation expense as compared to 2017. This change consisted of a decrease in the value of the plan assets of \$3,900,000 during 2018 as compared to an increase in the value of the plan assets of \$6,547,000 during 2017. The increase in interest income of \$1,457,000 was due to higher interest rates for our cash equivalents and short-term investments.

## Income Taxes

| (In thousands except percentages) | Fiscal Years |          | Percent Change |
|-----------------------------------|--------------|----------|----------------|
|                                   | 2018         | 2017     |                |
| Income taxes                      | \$21,063     | \$41,204 | (48.9 )%       |
| Percentage of total revenues      | 5.5 %        | 11.8 %   |                |
| Effective tax rate                | 22.6 %       | 49.9 %   |                |

The decrease in income tax expense was due to the impact of the U.S. tax legislation that was signed into law during the fourth quarter of 2017, partially offset by a decrease in the excess tax benefit associated with share-based payment awards. This U.S. tax legislation lowered the U.S. corporate income tax rate from 35% to 21% beginning in 2018. In addition, we recorded income tax expense of \$16,507,000 during the fourth quarter of 2017 associated with the tax legislation. We have domestic deferred tax assets primarily associated with our deferred compensation plan and stock-based compensation program, which were previously valued at the federal corporate income tax rate of 35%. Our deferred tax assets were re-measured at the lower enacted corporate tax rate of 21% which contributed \$15,137,000 to the fourth quarter of 2017 income tax expense associated with the tax legislation. We also have foreign earnings that were subject to the mandatory repatriation tax. The total mandatory repatriation tax, net of the benefit of our foreign tax credits, contributed \$1,370,000 to the fourth quarter of 2017 income tax expense associated with the tax legislation.

The excess tax benefit associated with share-based payment awards decreased to \$4,154,000 during 2018 as compared to \$6,528,000 during 2017.

Excluding the impact of the 2017 tax expense associated with the tax legislation and excluding the excess tax benefit, the effective tax rate would have been 27.0% for 2018 as compared to 37.8% for 2017. This decrease was due to the decrease in the U.S. corporate income tax rate from 35% to 21% beginning in 2018.

## **FISCAL YEARS ENDED DECEMBER 29, 2017, AND DECEMBER 30, 2016**

### **Revenues**

| (In thousands except percentages) | Fiscal Years |           | Percent Change |
|-----------------------------------|--------------|-----------|----------------|
|                                   | 2017         | 2016      |                |
| Engineering and Other Scientific  | \$277,603    | \$248,297 | 11.8 %         |
| Percentage of total revenues      | 79.8 %       | 78.8 %    |                |
| Environmental and Health          | 70,196       | 66,779    | 5.1 %          |
| Percentage of total revenues      | 20.2 %       | 21.2 %    |                |
| Total revenues                    | \$347,799    | \$315,076 | 10.4 %         |

The increase in revenues for our Engineering and Other Scientific segment was due to an increase in billable hours and an increase in billing rates. During 2017, billable hours for this segment increased by 9.9% to 941,000 as compared to 856,000 during 2016. The increase was due to demand for services in our construction consulting, human factors, mechanical engineering, and polymer science & materials chemistry practices. Reactive services continued to grow as our engineers and scientists were engaged to address construction disputes, medical device litigations, and consumer product and automobile recalls. Proactive services expanded, as we performed human factors assessments for consumer products and design consulting for consumer electronics. Utilization increased to 77% for 2017 as compared to 73% for 2016. Technical full-time equivalents increased 4.8% to 591 for 2017 from 564 for 2016 due to our recruiting and retention efforts.

The increase in revenues from our Environmental and Health segment was due to an increase in billable hours. During 2017, billable hours for this segment increased by 5.7% to 277,000 as compared to 262,000 during 2016. Utilization increased to 69% for 2017 as compared to 63% for 2016. During the year, the chemical regulation and food safety practice grew its proactive services to meet demand, as society remains concerned about chemicals affecting the global ecosystem and human health. Our environmental health scientists provided reactive services performing human health and environmental assessments. This segment's contribution to the large ongoing human factors assessment also contributed to the increase in billable hours and utilization. Technical full-time equivalents decreased 3.5% to 193 during 2017 as compared to 200 for 2016 due to our efforts to align resources with anticipated demand.

### Compensation and Related Expenses

| (In thousands except percentages) | Fiscal Years |           | Percent Change |
|-----------------------------------|--------------|-----------|----------------|
|                                   | 2017         | 2016      |                |
| Compensation and related expenses | \$210,289    | \$193,397 | 8.7 %          |
| Percentage of total revenues      | 60.5 %       | 61.4 %    |                |

The increase in compensation and related expenses during 2017 was due to an increase in bonus expense, an increase in payroll expense, an increase in fringe benefits, and a change in the value of assets associated with our deferred compensation plan. During 2017, bonus expense increased by \$7,718,000 due to a corresponding increase in income before income taxes, before bonus expense, and before stock-based compensation. During 2017, payroll and fringe benefits increased \$4,769,000 and \$991,000, respectively, due to the increase in technical full-time equivalent employees and our annual salary increase. During 2017, deferred compensation expense increased \$2,686,000 with a corresponding increase to other income as compared with the prior year due to the change in value of assets associated with our deferred compensation plan. This increase consisted of an increase in the value of the plan assets of \$6,547,000 during 2017 as compared to an increase in the value of the plan assets of \$3,861,000 during 2016.

### Other Operating Expenses

| (In thousands except percentages) | Fiscal Years |          | Percent Change |
|-----------------------------------|--------------|----------|----------------|
|                                   | 2017         | 2016     |                |
| Other operating Expenses          | \$29,544     | \$28,397 | 4.0 %          |
| Percentage of total revenues      | 8.5 %        | 9.0 %    |                |

Other operating expenses include facilities-related costs, technical materials, computer-related expenses and depreciation and amortization of property, equipment and leasehold improvements. The increase in other operating

expenses was primarily due to an increase in occupancy expense of \$416,000, an increase in computer expense of \$270,000, an increase in technical materials of \$183,000, and several individually insignificant increases, which were associated with the increase in technical full-time equivalent employees and investments in our corporate infrastructure.

#### Reimbursable Expenses

| (In thousands except percentages) | Fiscal Years |          | Percent Change |
|-----------------------------------|--------------|----------|----------------|
|                                   | 2017         | 2016     |                |
| Reimbursable expenses             | \$18,135     | \$15,879 | 14.2 %         |
| Percentage of total revenues      | 5.2 %        | 5.0 %    |                |

The increase in reimbursable expenses was primarily due to an increase in travel related costs associated with our large human factors assessment project. The amount of reimbursable expenses will vary from year to year depending on the nature of our projects.

#### General and Administrative Expenses

| (In thousands except percentages)   | Fiscal Years |          | Percent Change |
|-------------------------------------|--------------|----------|----------------|
|                                     | 2017         | 2016     |                |
| General and administrative expenses | \$17,780     | \$15,492 | 14.8 %         |
| Percentage of total revenues        | 5.1 %        | 4.9 %    |                |

The increase in general and administrative expenses during 2017 was primarily due to an increase in travel and meals of \$1,173,000, an increase in contributions of \$250,000, an increase in marketing and promotion of \$200,000 and an increase in legal expense of \$194,000. The increase in travel and meals was due to a firm-wide managers' meeting which occurs every other year. The increase in marketing and promotion was due to several initiatives associated with the firm's 50<sup>th</sup> anniversary.

## Other Income

| (In thousands except percentages) | Fiscal Years |         | Percent Change |
|-----------------------------------|--------------|---------|----------------|
|                                   | 2017         | 2016    |                |
| Other income                      | \$10,458     | \$7,211 | 45.0 %         |
| Percentage of total revenues      | 3.0 %        | 2.3 %   |                |

Other income consists primarily of interest income earned on available cash, cash equivalents and short-term investments, changes in the value of assets associated with our deferred compensation plan and rental income from leasing excess space in our Silicon Valley facility. The increase in other income was primarily due to the change in value of assets associated with our deferred compensation plan. During 2017, other income increased \$2,686,000 with a corresponding increase to deferred compensation expense as compared to 2016. This change consisted of an increase in the value of the plan assets of \$6,547,000 during 2017 as compared to an increase in the value of the plan assets of \$3,861,000 during 2016. The increase in other income during 2017 was also due to an increase in interest income of \$611,000 due to higher interest rates for our cash equivalents and short-term investments.

## Income Taxes

| (In thousands except percentages) | Fiscal Years |          | Percent Change |
|-----------------------------------|--------------|----------|----------------|
|                                   | 2017         | 2016     |                |
| Income taxes                      | \$41,204     | \$21,642 | 90.4 %         |
| Percentage of total revenues      | 11.8 %       | 6.9 %    |                |
| Effective tax rate                | 49.9 %       | 31.3 %   |                |

The increase in income tax expense was due to an increase in pre-tax income and the impact of the tax legislation signed into law during the fourth quarter of 2017, partially offset by an increase in the excess tax benefit associated with share-based payment awards. During 2017, we recorded a tax expense of \$16,507,000 related to the tax legislation. We have significant domestic deferred tax assets primarily associated with our deferred compensation plan and stock-based compensation program, which were previously valued at the federal corporate income tax rate of 35%. Our deferred tax assets were re-measured at the lower enacted corporate tax rate of 21%, which contributed \$15,137,000 to the increase in income tax associated with the tax legislation. We also have foreign earnings that were subject to the mandatory repatriation tax. The total mandatory repatriation tax, net of the benefit of our foreign tax credits, contributed \$1,370,000 to the increase in income tax expense associated with the tax legislation.

The excess tax benefit associated with share-based payment awards increased to \$6,528,000 during 2017 as compared to \$4,827,000 during 2016. Excluding the impact of the tax legislation and the excess tax benefit, the effective tax rate would have been 37.8% for 2017 as compared to 38.3% for 2016.

## LIQUIDITY AND CAPITAL RESOURCES

| (In thousands)                  | Fiscal Years |            |            |
|---------------------------------|--------------|------------|------------|
|                                 | 2018         | 2017       | 2016       |
| Net cash provided by (used in): |              |            |            |
| Operating activities            | \$91,188     | \$67,838   | \$66,946   |
| Investing activities            | \$(25,820)   | \$(17,722) | \$(27,443) |
| Financing activities            | \$(62,500)   | \$(41,261) | \$(49,166) |

We financed our business in 2018 through available cash and cash flows from operating activities. We invest our excess cash in cash equivalents and short-term investments. As of December 28, 2018, our cash, cash equivalents and short-term investments were \$208,554,000 as compared to \$196,398,000 at December 29, 2017. We believe our existing balances of cash, cash equivalents and short-term investments will be sufficient to satisfy our working capital needs, capital expenditures, outstanding commitments, stock repurchases, dividends and other liquidity requirements over at least the next 12 months.

Generally, our net cash provided by operating activities is used to fund our day-to-day operating activities. First quarter operating cash requirements are generally higher due to payment of our annual bonuses accrued during the prior year. Our largest source of operating cash flows is cash collections from our clients. Our primary uses of cash from operating activities are for employee-related expenditures, leased facilities, taxes, and general operating expenses including marketing and travel.

Net cash provided by operating activities was \$91.2 million for 2018 as compared to \$67.8 million and \$66.9 million in 2017 and 2016, respectively. The increase in net cash provided by operating activities during 2018 was primarily due to the increase in net income and a decrease in accounts receivable.

During 2018, 2017 and 2016, net cash used in investing activities was primarily related to the purchase and maturity of short-term investments and capital expenditures. During 2018, we purchased 2.9 acres of land in Natick, Massachusetts, on which we are currently building office and laboratory facilities. The total purchase price for the land was \$5.2 million and our total capital expenditures during 2018 associated with the construction were \$5.3 million. During 2016, we completed the purchase of a 1.1 acre parcel of land with 27,000 square feet of warehouse storage space in Menlo Park, California, adjacent to our owned office and lab facilities. We had leased this warehouse storage space for the past 25 years. The total purchase price was \$8,250,000.

The increase in net cash used in financing activities during 2018 as compared to 2017 was due to an increase in our quarterly dividend payments and an increase in repurchases of our common stock. The decrease in net cash used in financing activities during 2017, as compared to 2016, was due to a decrease in repurchases of our common stock partially offset by an increase in our quarterly dividend payments.

We expect to continue our investing activities, including capital expenditures. Furthermore, cash reserves may be used to repurchase common stock under our stock repurchase programs, pay dividends, procure facilities and equipment or strategically acquire professional service firms that are complementary to our business.

The following schedule summarizes our principal contractual commitments as of December 28, 2018 (in thousands):

| Fiscal year | Operating lease commitments | Purchase Obligations | Total     |
|-------------|-----------------------------|----------------------|-----------|
| 2019        | \$ 7,220                    | \$ 12,315            | \$ 19,535 |
| 2020        | 5,988                       | -                    | 5,988     |
| 2021        | 4,940                       | -                    | 4,940     |
| 2022        | 3,887                       | -                    | 3,887     |
| 2023        | 2,600                       | -                    | 2,600     |
| Thereafter  | 6,157                       | -                    | 6,157     |
|             | \$ 30,792                   | \$ 12,315            | \$ 43,107 |

Purchase obligations disclosed in the table above include \$11,769,000 associated with the construction of our office and laboratory facilities in Natick, Massachusetts. The above table does not reflect unrecognized tax benefits of \$1,748,000, the timing of which is uncertain. Refer to "Note 7: Income Taxes" of the *Notes to Consolidated Financial Statements* for additional discussion on unrecognized tax benefits.

We maintain nonqualified deferred compensation plans for the benefit of a select group of highly compensated employees. Vested amounts due under the plans of \$52,708,000 were recorded as a long-term liability on our consolidated balance sheet at December 28, 2018. Vested amounts due under the plans of \$6,641,000 were recorded as a current liability on our consolidated balance sheet at December 28, 2018. Company assets that are earmarked to pay benefits under the plans are held in a rabbi trust and are subject to the claims of our creditors. As of December 28, 2018, invested amounts under the plans of \$52,286,000 were recorded as a long-term asset on our consolidated balance sheet. As of December 28, 2018, invested amounts under the plans of \$5,492,000 were recorded as a current asset on our consolidated balance sheet.

As permitted under Delaware law, we have agreements whereby we indemnify our officers and directors for certain events or occurrences while the officer or director is, or was serving, at our request in such capacity. The indemnification period covers all pertinent events and occurrences during the officer's or director's lifetime. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have director and officer insurance coverage that reduces our exposure and enables us to recover a portion of any future amounts paid. We believe the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal.

#### **Off-Balance Sheet Arrangements**

As part of our ongoing business, we do not engage in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities.



## Non-GAAP Financial Measures

Regulation G, conditions for use of Non-Generally Accepted Accounting Principles (“Non-GAAP”) financial measures, and other SEC regulations define and prescribe the conditions for use of certain Non-GAAP financial information. Generally, a Non-GAAP financial measure is a numerical measure of a company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. We closely monitor two financial measures, EBITDA and EBITDAS, which meet the definition of Non-GAAP financial measures. We define EBITDA as net income before income taxes, interest income, depreciation and amortization. We define EBITDAS as EBITDA before stock-based compensation. We regard EBITDA and EBITDAS as useful measures of operating performance and cash flow to complement operating income, net income and other GAAP financial performance measures. Additionally, management believes that EBITDA and EBITDAS provide meaningful comparisons of past, present and future operating results. These measures are used to evaluate our financial results, develop budgets and determine employee compensation. These measures, however, should be considered in addition to, and not as a substitute or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP. A reconciliation of the Non-GAAP measures to the nearest comparable GAAP measure is set forth below.

The following table shows EBITDA as a percentage of revenues before reimbursements for fiscal years 2018, 2017 and 2016:

| (in thousands, except percentages)              | Fiscal Years |           |           |
|---|--------------|-----------|-----------|
|   | 2018         | 2017      | 2016      |
| Revenues before reimbursements                  | \$354,639    | \$329,664 | \$299,197 |
| EBITDA  | \$96,858     | \$87,500  | \$74,570  |
| EBITDA as a % of revenues before reimbursements | 27.3 %       | 26.5 %    | 24.9 %    |

The increase in EBITDA as a percentage of revenues before reimbursements for 2018 as compared to 2017 was due to 8% growth in revenues before reimbursements, a 1% decrease in general and administrative expenses and a 4% increase in other operating expenses. The decrease in general and administrative expenses was due to a firm-wide managers’ meeting during 2017. Other operating expenses increased at a lower rate than our revenues before reimbursements due to the leverage of our corporate infrastructure.

The increase in EBITDA as a percentage of revenues before reimbursements for 2017 as compared to 2016 was primarily due to an increase in utilization. Utilization for 2017 was 75% as compared to 70% for the prior period. The increase in utilization was due to strong demand for both our proactive and reactive services and the impact of the

large human factors assessments we performed for a client in the consumer products industry.

The following table is a reconciliation of EBITDA and EBITDAS to the most comparable GAAP measure, net income, for fiscal 2018, 2017 and 2016:

| (in thousands)                | Fiscal Years |           |          |
|-------------------------------|--------------|-----------|----------|
|                               | 2018         | 2017      | 2016     |
| Net Income                    | \$72,254     | \$41,305  | \$47,480 |
| Add back (subtract):          |              |           |          |
| Income taxes                  | 21,063       | 41,204    | 21,642   |
| Interest income, net          | (2,751 )     | (1,294 )  | (683 )   |
| Depreciation and amortization | 6,292        | 6,285     | 6,131    |
| EBITDA                        | 96,858       | 87,500    | 74,570   |
| Stock-based compensation      | 16,993       | 16,155    | 13,333   |
| EBITDAS                       | \$113,851    | \$103,655 | \$87,903 |

#### Item 7A. Quantitative and Qualitative Disclosure About Market Risk

Exponent is exposed to interest rate risk associated with our balances of cash, cash equivalents and short-term investments. We manage our interest rate risk by maintaining an investment portfolio primarily consisting of debt instruments with high credit quality and relatively short average effective maturities in accordance with the Company's investment policy. The maximum effective maturity of any issue in our portfolio of cash equivalents and short-term investments is 3 years and the maximum average effective maturity of the portfolio cannot exceed 12 months.

If interest rates were to instantaneously increase or decrease by 100 basis points, the change in the fair value of our portfolio of cash equivalents and short-term investments would not have a material impact on our financial statements. We do not use derivative financial instruments in our investment portfolio. Notwithstanding our efforts to manage interest rate risk, there can be no assurances that we will be adequately protected against the risks associated with interest rate fluctuations.

We have foreign currency risk related to our revenues and expenses denominated in currencies other than the U.S. dollar, primarily the British Pound, the Euro, and the Chinese Yuan. Accordingly, changes in exchange rates may negatively affect the revenues and net income of our foreign subsidiaries as expressed in U.S. dollars.

At December 28, 2018, we had net assets of approximately \$5.4 million with a functional currency of the British Pound, net assets of approximately \$5.4 million with a functional currency of the Euro, and net assets of approximately \$5.4 million with a functional currency of the Chinese Yuan associated with our operations in the United Kingdom, Germany, and China, respectively.

We also have foreign currency risk related to foreign currency transactions and monetary assets and liabilities denominated in currencies that are not the functional currency. We have experienced and will continue to experience fluctuations in our net income as a result of gains (losses) on these foreign currency transactions and the re-measurement of monetary assets and liabilities. At December 28, 2018, we had net assets denominated in the non-functional currency of approximately \$2.0 million.

We do not use foreign exchange contracts to hedge any foreign currency exposures. To date, the impacts of foreign currency exchange rate changes on our consolidated revenues and consolidated net income have not been material. However, our continued international expansion increases our exposure to exchange rate fluctuations and as a result such fluctuations could have a significant impact on our future results of operations.

Item 8. Financial Statements and Supplementary Data

See Item 15 of this Form 10-K for required financial statements and supplementary data.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

KPMG LLP, an independent registered public accounting firm, has audited the internal control over financial reporting of Exponent, Inc., as stated in their report which is included in Part IV, Item 15 of this Form 10-K.

**(a) Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures.**

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13(a)-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this annual report.

**(b) Management’s Report on Internal Control Over Financial Reporting.**

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Our internal control over financial reporting is designed to provide reasonable assurance, but not absolute assurance, regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. generally accepted accounting principles. There are inherent limitations to the effectiveness of any system of internal control over financial reporting. These limitations include the possibility of human error, the circumvention or overriding of the system and reasonable resource constraints. Because of its inherent limitations, our internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that

controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in *Internal Control - Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in *Internal Control - Integrated Framework (2013)*, our management concluded that our internal control over financial reporting was effective at the reasonable assurance level as of December 28, 2018.

(c) **Changes in Internal Control Over Financial Reporting.**

There have not been any changes in the Company's internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act, during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

**Item 9B. Other Information**

None.

**PART III**

Certain information required by Part III is omitted from this Annual Report on Form 10-K. We intend to file a definitive Proxy Statement pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and certain information included therein is incorporated herein by reference.

**Item 10. Directors, Executive Officers and Corporate Governance**

The information required by this item is incorporated by reference to the Company's definitive Proxy Statement for its 2019 Annual Meeting of Stockholders (the "Proxy Statement"). See Part 1, Item 1 of this Annual Report on Form 10-K for information regarding the executive officers of the Company.

Item 11. Executive Compensation

The information required by this item is incorporated by reference to the Proxy Statement.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this item is incorporated by reference to the Proxy Statement. See also the table on the Company's share repurchases in Part II, Item 5 above.

Item 13. Certain Relationships and Related Transactions, and Director Independence

The information required by this item is incorporated by reference to the Proxy Statement.

**Item 14. Principal Accounting Fees and Services**

The information required by this item is incorporated by reference to the Proxy Statement.

PART IV

Item 15. Exhibits, Financial Statement Schedules

**(a) The following documents are filed as part of this Annual Report on Form 10-K.**

1. Financial Statements

The following consolidated financial statements of Exponent, Inc. and subsidiaries and the Report of Independent Registered Public Accounting Firm are included herewith:

|   | Page      |
|---|-----------|
| <u>Report of Independent Registered Public Accounting Firm</u>  | <u>34</u> |
| <u>Consolidated Statements of Income for the years ended December 28, 2018, December 29, 2017 and December 30, 2016</u>               | <u>36</u> |
| <u>Consolidated Statements of Comprehensive Income for the years ended December 28, 2018, December 29, 2017 and December 30, 2016</u> | <u>37</u> |
| <u>Consolidated Balance Sheets as of December 28, 2018 and December 29, 2017</u>  | <u>38</u> |
| <u>Consolidated Statements of Stockholders' Equity for the years ended December 28, 2018, December 29, 2017 and December 30, 2016</u> | <u>39</u> |
| <u>Consolidated Statements of Cash Flows for the years ended December 28, 2018, December 29, 2017 and December 30, 2016</u>           | <u>41</u> |
| <u>Notes to Consolidated Financial Statements</u>   | <u>42</u> |

2. Financial Statement Schedules



The following financial statement schedule of Exponent, Inc. for the years ended December 28, 2018, December 29, 2017 and December 30, 2016 is filed as part of this Report and should be read in conjunction with the consolidated financial statements of Exponent, Inc. and subsidiaries:

**Page**

Schedule II - Valuation and Qualifying Accounts 60

Schedules other than those listed above have been omitted since they are either not required, not applicable, or the information is otherwise included elsewhere in the report.

3.

Exhibits

**Page**

(a) Exhibit Index 61

## Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors

Exponent, Inc.:

### Opinions on the Consolidated Financial Statements and Internal Control Over Financial Reporting

We have audited the accompanying consolidated balance sheets of Exponent, Inc. and subsidiaries (the Company) as of December 28, 2018 and December 29, 2017, the related consolidated statements of income, comprehensive income, stockholders' equity, and cash flows for each of the years in the three-year period ended December 28, 2018, and the related notes and financial statement schedule II (collectively, the consolidated financial statements). We also have audited the Company's internal control over financial reporting as of December 28, 2018, based on criteria established in *Internal Control – Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 28, 2018 and December 29, 2017, and the results of its operations and its cash flows for each of the years in the three-year period ended December 28, 2018, in conformity with U.S. generally accepted accounting principles. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 28, 2018 based on criteria established in *Internal Control – Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission.

### Basis for Opinions

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management Report on Internal Control over Financial Reporting, appearing under Item 9A(b). Our responsibility is to express an opinion on the Company's consolidated financial statements and an opinion on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

## Definition and Limitations of Internal Control Over Financial Reporting

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ KPMG LLP

We have served as the Company's auditor since 1987.

San Francisco, California  
February 22, 2019

**Exponent, Inc. and Subsidiaries**

## Consolidated Statements of Income

| (In thousands, except per share data)    | Fiscal Years |           |           |
|--|--------------|-----------|-----------|
|  | 2018         | 2017      | 2016      |
| Revenues:                                |              |           |           |
| Revenues before reimbursements           | \$354,639    | \$329,664 | \$299,197 |
| Reimbursements                           | 24,884       | 18,135    | 15,879    |
| Revenues                                 | 379,523      | 347,799   | 315,076   |
| Operating expenses:                      |              |           |           |
| Compensation and related expenses        | 215,052      | 210,289   | 193,397   |
| Other operating expenses                 | 30,599       | 29,544    | 28,397    |
| Reimbursable expenses                    | 24,884       | 18,135    | 15,879    |
| General and administrative expenses      | 17,532       | 17,780    | 15,492    |
|  | 288,067      | 275,748   | 253,165   |
| Operating income                         | 91,456       | 72,051    | 61,911    |
| Other income:                            |              |           |           |
| Interest income                          | 2,751        | 1,294     | 683       |
| Miscellaneous income, net                | (890 )       | 9,164     | 6,528     |
| Income before income taxes               | 93,317       | 82,509    | 69,122    |
| Provision for income taxes               | 21,063       | 41,204    | 21,642    |
| Net income                               | \$72,254     | \$41,305  | \$47,480  |
| Net income per share:                    |              |           |           |
| Basic                                    | \$1.37       | \$0.78    | \$0.90    |
| Diluted                                  | \$1.33       | \$0.77    | \$0.87    |
| Shares used in per share computations:   |              |           |           |
| Basic                                    | 52,906       | 52,724    | 52,976    |
| Diluted                                  | 54,168       | 53,972    | 54,332    |
| Cash dividends declared per common share | \$0.52       | \$0.42    | \$0.36    |

See accompanying notes to the Consolidated Financial Statements.

**Exponent, Inc. and Subsidiaries**

## Consolidated Statements of Comprehensive Income

| (In thousands)  | Fiscal Years |          |          |
|---|--------------|----------|----------|
|   | 2018         | 2017     | 2016     |
| Net income  | \$72,254     | \$41,305 | \$47,480 |
| Other comprehensive (loss) income, net of tax:  |              |          |          |
| Foreign currency translation adjustments, net of tax of \$0, \$0, and \$0, respectively                             | (1,015 )     | 1,187    | (1,240 ) |
| Unrealized gain/(loss) arising during the period on investments, net of tax of \$(63), \$60, and \$53, respectively | 191          | (90 )    | (81 )    |
| Comprehensive income  | \$71,430     | \$42,402 | \$46,159 |

See accompanying notes to the Consolidated Financial Statements.

**Exponent, Inc. and Subsidiaries****Consolidated Balance Sheets**

| (In thousands, except par value)   | December 28,<br>2018 | December 29,<br>2017 |
|--|----------------------|----------------------|
| <b>Assets</b>  |                      |                      |
| Current assets:  |                      |                      |
| Cash and cash equivalents  | \$ 127,059           | \$ 124,794           |
| Short-term investments   | 81,495               | 71,604               |
| Accounts receivable, net of allowance for contract losses and doubtful accounts of \$4,066 and \$3,526, respectively | 105,814              | 110,100              |
| Prepaid expenses and other assets  | 12,244               | 9,011                |
| Total current assets   | 326,612              | 315,509              |
| Property, equipment and leasehold improvements, net  | 46,103               | 35,014               |
| Goodwill   | 8,607                | 8,607                |
| Deferred income taxes  | 34,090               | 30,437               |
| Deferred compensation plan assets  | 52,286               | 48,676               |
| Other assets   | 1,238                | 1,346                |
|  | \$ 468,936           | \$ 439,589           |
| <b>Liabilities and Stockholders' Equity</b>  |                      |                      |
| Current liabilities:   |                      |                      |
| Accounts payable and accrued liabilities   | \$ 12,283            | \$ 14,741            |
| Accrued payroll and employee benefits  | 76,855               | 70,064               |
| Deferred revenues  | 9,166                | 8,302                |
| Total current liabilities  | 98,304               | 93,107               |
| Other liabilities  | 2,548                | 3,326                |
| Deferred compensation plan liabilities   | 52,708               | 52,776               |
| Deferred rent  | 1,467                | 1,292                |
| Total liabilities  | 155,027              | 150,501              |
| Commitments and contingencies (Note 12)  |                      |                      |
| Stockholders' equity:  |                      |                      |
| Preferred stock, \$.001 par value; 2,000 shares authorized; no shares outstanding                                    | -                    | -                    |
| Common stock, \$.001 par value; 120,000 shares authorized; 65,707 shares issued                                      | 66                   | 66                   |
| Additional paid-in capital   | 227,283              | 210,230              |
| Accumulated other comprehensive (loss)   |                      |                      |

Edgar Filing: EXPONENT INC - Form 10-K

|  |            |   |            |   |
|--|------------|---|------------|---|
| Investment securities, available for sale                            | (45        | ) | (236       | ) |
| Foreign currency translation adjustments                             | (2,808     | ) | (1,793     | ) |
|  | (2,853     | ) | (2,029     | ) |
| Retained earnings  | 342,024    |   | 303,990    |   |
| Treasury stock, at cost: 14,208 and 14,169 shares held, respectively | (252,611   | ) | (223,169   | ) |
| Total stockholders' equity   | 313,909    |   | 289,088    |   |
|  | \$ 468,936 |   | \$ 439,589 |   |

See accompanying notes to the Consolidated Financial Statements.



## Exponent, Inc. and Subsidiaries

## Consolidated Statements of Stockholders' Equity

| (In thousands)  | Common Stock |        | Additional<br>paid-in<br>capital | Accumulated<br>other<br>comprehensive<br>income<br>(loss) | Retained<br>earnings | Treasury Stock |              | Total      |
|---|--------------|--------|----------------------------------|---|----------------------|----------------|--------------|------------|
|   | Shares       | Amount |                                  |   |                      | Shares         | Amount       |            |
| Balance at January 1, 2016                              | 65,707       | \$ 66  | \$ 179,783                       | \$ (1,805 )   | \$ 269,259           | 14,266         | \$(184,499 ) | \$ 262,804 |
| Employee stock purchase plan                            | -            | -      | 883                              | -   | -                    | (46 )          | 307          | 1,190      |
| Exercise of stock options                               | -            | -      | 161                              | -   | -                    | (60 )          | 405          | 566        |
| Amortization of unrecognized stock-based compensation   | -            | -      | 7,152                            | -   | -                    | -              | -            | 7,152      |
| Purchase of treasury shares                             | -            | -      | -                                | -   | -                    | 982            | (24,456 )    | (24,456 )  |
| Foreign currency translation adjustments                | -            | -      | -                                | (1,240 )  | -                    | -              | -            | (1,240 )   |
| Grant of restricted stock units to settle accrued bonus | -            | -      | 6,334                            | -   | -                    | -              | -            | 6,334      |
| Settlement of restricted stock units                    | -            | -      | (701 )                           | -   | (5,791 )             | (630 )         | (1,193 )     | (7,685 )   |
| Unrealized loss on investments                          | -            | -      | -                                | (81 )   | -                    | -              | -            | (81 )      |
| Dividends and dividend equivalent rights                | -            | -      | 854                              | -   | (19,627 )            | -              | -            | (18,773 )  |
| Other   | -            | -      | 133                              | -   | (78 )                | -              | -            | 55         |
| Net income  | -            | -      | -                                | -   | 47,480               | -              | -            | 47,480     |
| Balance at December 30, 2016                            | 65,707       | \$ 66  | \$ 194,599                       | \$ (3,126 )   | \$ 291,243           | 14,512         | \$(209,436 ) | \$ 273,346 |
| Employee stock purchase plan                            | -            | -      | 847                              | -   | -                    | (40 )          | 360          | 1,207      |
| Exercise of stock options                               | -            | -      | 144                              | -   | -                    | (69 )          | 674          | 818        |
| Amortization of unrecognized stock-based compensation   | -            | -      | 7,824                            | -   | -                    | -              | -            | 7,824      |
| Purchase of treasury shares                             | -            | -      | -                                | -   | -                    | 372            | (11,931 )    | (11,931 )  |
| Foreign currency translation adjustments                | -            | -      | -                                | 1,187   | -                    | -              | -            | 1,187      |

Edgar Filing: EXPONENT INC - Form 10-K

|   |        |       |            |             |            |        |              |            |
|---|--------|-------|------------|-------------|------------|--------|--------------|------------|
| Grant of restricted stock units to settle accrued bonus | -      | -     | 6,918      | -           | -          | -      | -            | 6,918      |
| Settlement of restricted stock units                    | -      | -     | (1,017 )   | -           | (5,667 )   | (606 ) | (2,836 )     | (9,520 )   |
| Unrealized loss on investments                          | -      | -     | -          | (90 )       | -          | -      | -            | (90 )      |
| Dividends and dividend equivalent rights                | -      | -     | 915        | -           | (22,891 )  | -      | -            | (21,976 )  |
| Net income  | -      | -     | -          | -           | 41,305     | -      | -            | 41,305     |
| Balance at December 29, 2017                            | 65,707 | \$ 66 | \$ 210,230 | \$ (2,029 ) | \$ 303,990 | 14,169 | \$ (223,169) | \$ 289,088 |

See accompanying notes to the Consolidated Financial Statements.

Edgar Filing: EXPONENT INC - Form 10-K

| (In thousands)  | Common Stock |        | Additional<br>paid-in<br>capital | Accumulated<br>other<br>comprehensive<br>income<br>(loss) | Retained<br>earnings | Treasury Stock |             | Total      |
|---|--------------|--------|----------------------------------|---|----------------------|----------------|-------------|------------|
|   | Shares       | Amount |                                  |   |                      | Shares         | Amount      |            |
| Balance at December 29,<br>2017                               | 65,707       | \$ 66  | \$ 210,230                       | \$ (2,029 )   | \$ 303,990           | 14,169         | \$(223,169) | \$ 289,088 |
| Employee stock purchase<br>plan                               | -            | -      | 1,161                            | -   | -                    | (32 )          | 313         | 1,474      |
| Amortization of<br>unrecognized stock-based<br>compensation   | -            | -      | 8,550                            | -   | -                    | -              | -           | 8,550      |
| Purchase of treasury<br>shares                                | -            | -      | -                                | -   | -                    | 562            | (27,915 )   | (27,915 )  |
| Foreign currency<br>translation adjustments                   | -            | -      | -                                | (1,015 )  | -                    | -              | -           | (1,015 )   |
| Grant of restricted stock<br>units to settle accrued<br>bonus | -            | -      | 7,643                            | -   | -                    | -              | -           | 7,643      |
| Settlement of restricted<br>stock units                       | -            | -      | (1,107 )                         | -   | (5,892 )             | (491 )         | (1,840 )    | (8,839 )   |
| Unrealized gain on<br>investments                             | -            | -      | -                                | 191   | -                    | -              | -           | 191        |
| Dividends and dividend<br>equivalent rights                   | -            | -      | 806                              | -   | (28,328 )            | -              | -           | (27,522 )  |
| Net income  | -            | -      | -                                | -   | 72,254               | -              | -           | 72,254     |
| Balance at<br>December 28, 2018                               | 65,707       | \$ 66  | \$ 227,283                       | \$ (2,853 )   | \$ 342,024           | 14,208         | \$(252,611) | \$ 313,909 |

See accompanying notes to the Consolidated Financial Statements.

Exponent, Inc. and Subsidiaries

**Consolidated Statements of Cash Flows**

| (In thousands)  | Fiscal Years |           |           |
|---|--------------|-----------|-----------|
|   | 2018         | 2017      | 2016      |
| Cash flows from operating activities:   |              |           |           |
| Net income  | \$72,254     | \$41,305  | \$47,480  |
| Adjustments to reconcile net income to net cash provided by operating activities: |              |           |           |
| Depreciation and amortization of property, equipment and leasehold improvements   | 6,292        | 6,285     | 6,131     |
| Amortization of premiums and accretion of discounts on short-term investments     | (114 )       | -         | 2         |
| Deferred rent expense   | 175          | (362 )    | (340 )    |
| Provision for contract losses and doubtful accounts                               | 1,848        | 2,506     | 2,452     |
| Stock-based compensation  | 16,993       | 16,155    | 13,333    |
| Deferred income tax provision   | (3,715 )     | 11,786    | (2,602 )  |
| Changes in operating assets and liabilities:                                      |              |           |           |
| Accounts receivable   | 2,438        | (25,197 ) | (1,284 )  |
| Prepaid expenses and other assets   | (11,047 )    | 2,867     | (598 )    |
| Accounts payable and accrued liabilities  | (4,620 )     | 5,984     | (370 )    |
| Accrued payroll and employee benefits   | 9,820        | 5,831     | 2,920     |
| Deferred revenues   | 864          | 678       | (178 )    |
| Net cash provided by operating activities   | 91,188       | 67,838    | 66,946    |
| Cash flows from investing activities:   |              |           |           |
| Capital expenditures  | (16,298 )    | (4,725 )  | (14,393 ) |
| Purchase of short-term investments  | (52,522 )    | (28,997 ) | (51,000 ) |
| Maturity of short-term investments  | 43,000       | 16,000    | 37,950    |
| Net cash used in investing activities   | (25,820 )    | (17,722 ) | (27,443 ) |
| Cash flows from financing activities:   |              |           |           |
| Payroll taxes for restricted stock units  | (8,839 )     | (9,520 )  | (7,685 )  |
| Repurchase of common stock  | (27,915 )    | (11,931 ) | (24,456 ) |
| Exercise of share-based payment awards  | 1,474        | 2,025     | 1,756     |
| Dividends and dividend equivalent rights  | (27,220 )    | (21,835 ) | (18,781 ) |
| Net cash used in financing activities   | (62,500 )    | (41,261 ) | (49,166 ) |
| Effect of foreign currency exchange rates on cash and cash equivalents            | (603 )       | 972       | (1,121 )  |
| Net increase (decrease) in cash and cash equivalents                              | 2,265        | 9,827     | (10,784 ) |
| Cash and cash equivalents at beginning of year                                    | 124,794      | 114,967   | 125,751   |
| Cash and cash equivalents at end of year  | \$127,059    | \$124,794 | \$114,967 |

See accompanying notes to the Consolidated Financial Statements.



## **Exponent, Inc. and Subsidiaries**

### **Notes to Consolidated Financial Statements**

#### Note 1: Summary of Significant Accounting Policies

##### Basis of Presentation

Exponent, Inc. together with its subsidiaries (collectively referred to as the “Company”) is a science and engineering consulting firm that provides solutions to complex problems. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.

The Company operates on a 52-53 week fiscal year with each year ending on the Friday closest to December 31<sup>st</sup>. Fiscal periods 2018, 2017 and 2016 included 52 weeks of activity and ended on December 28, 2018, December 29, 2017 and December 30, 2016, respectively. Fiscal period 2019 is 53 weeks and will end on January 3, 2020.

##### **Stock Split**

On May 31, 2018, the Company’s stockholders approved an amendment to the Company’s certificate of incorporation to (i) increase the number of authorized shares of common stock to 120,000,000 and (ii) effect a two-for-one stock split. As a result of the stock split, each shareholder of record at the close of business on May 31, 2018, received one additional share of common stock for each share of common stock owned by such stockholder. Restricted stock unit awards and stock option awards have also been adjusted to reflect the two-for-one stock split. For periods prior to the stock split, all share and per share data in the Company’s consolidated financial statements and related notes have been retroactively adjusted to reflect the stock split.

##### Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets

and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Estimates are used for, but not limited to, revenue recognition, allowance for contract losses and doubtful accounts, stock-based compensation, income taxes, goodwill, and the useful life of property, equipment and leasehold improvements. Actual results could differ from those estimates.

### **Foreign Currency Translation**

The Company translates the assets and liabilities of foreign subsidiaries, whose functional currency is the local currency, at exchange rates in effect at the balance sheet date. Revenues and expenses are translated at the average rates of exchange prevailing during the year. The adjustment resulting from translating the financial statements of such foreign subsidiaries is included in accumulated other comprehensive income, which is reflected as a separate component of stockholders' equity.

### **Cash Equivalents**

Cash equivalents consist of highly liquid investments such as money market mutual funds, commercial paper and debt securities with original remaining maturities of three months or less from the date of purchase.

### **Short-term Investments**

Short-term investments consist of debt securities classified as available-for-sale and are carried at their fair value as of the balance sheet date. Short-term investments generally mature between three months and three years from the purchase date. Investments with maturities beyond one year are classified as short-term based on their highly liquid nature and because such marketable securities represent investments readily available for current operations.

The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest income. Realized gains or losses are determined on the specific identification method and are reflected in other income. Net unrealized gains and losses are recorded directly in accumulated other comprehensive income except for unrealized losses that are deemed to be other-than-temporary, which are reflected in net income.

Investments are reviewed on a regular basis to evaluate whether or not any security has experienced an other-than temporary decline in fair value. When assessing investments for other-than-temporary declines in fair value, the Company considers the significance of the decline in value as a percentage of the original cost, how long the market value of the investment has been less than its original cost, any news that has been released specific to the investee,

and the Company's intent to sell, or whether it is more likely than not it will be required to sell the investment before recovery of the investment's cost basis.



### **Allowances for Contract Losses and Doubtful Accounts**

The Company maintains allowances for estimated losses resulting from the inability of customers to meet their financial obligations or for disputes that affect the Company's ability to fully collect amounts due. In circumstances where the Company is aware of a specific customer's inability to meet its financial obligations or aware of a dispute with a specific customer, a specific allowance is recorded to reduce the net recognized receivable to the amount the Company reasonably believes will be collected. For all other customers the Company recognizes allowances for doubtful accounts based upon historical write-offs, customer concentration, customer credit-worthiness, current economic conditions, aging of amounts due and changes in customer payment terms.

### **Property, Equipment and Leasehold Improvements**

Property, equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Buildings are depreciated over their estimated useful lives ranging from thirty to forty years. Equipment is depreciated over its estimated useful life, which generally ranges from two to seven years. Leasehold improvements are amortized over the shorter of their estimated useful lives, generally seven years, or the term of the related lease.

### **Impairment of Long-Lived Assets**

The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to future undiscounted cash flows to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. The Company has not recognized impairment losses on any long-lived assets in fiscal years 2018, 2017 or 2016.

### **Goodwill**

The Company assesses the impairment of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may be impaired. The Company's annual goodwill impairment review is completed during the fourth quarter of each year. The Company evaluates goodwill for each reporting unit for impairment by assessing qualitative factors to determine whether it is necessary to perform a quantitative goodwill impairment test.

The Company considers events and circumstances, including but not limited to, macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, changes in management or key personnel, changes in strategy, changes in customers, a change in the composition or carrying amount of a reporting unit's net assets and changes in the price of its common stock. If, after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then the quantitative goodwill impairment test is not performed.

The Company completed its annual assessment for all reporting units with goodwill for fiscal 2018 and determined, after assessing the totality of the qualitative factors, that it is more likely than not that the fair value of each reporting unit is greater than its respective carrying amount. Accordingly there was no indication of impairment of goodwill for any of the Company's reporting units and the quantitative goodwill impairment test was not performed. The Company did not recognize any goodwill impairment losses in fiscal years 2018, 2017 or 2016.

#### Deferred Revenues

Deferred revenues represent amounts billed to clients in advance of services provided.

#### Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax basis and the financial reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities from changes in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized. An uncertain tax position is recognized if it is determined that it is more likely than not to be sustained upon examination. The tax position is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company's policy is to recognize interest and penalties related to unrecognized tax benefits as income tax expense. Accrued interest and penalties are insignificant at December 28, 2018 and December 29, 2017.

## Fair Value of Financial Instruments

Financial instruments consist of cash and cash equivalents, short-term investments, accounts receivable, other assets and accounts payable. Cash, cash equivalents and short-term investments are recorded at fair value. The carrying amount of the Company's accounts receivable, other assets and accounts payable approximates their fair values due to their short maturities.

## Stock-Based Compensation

Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period of the entire award. The Company accounts for forfeitures of share-based awards when they occur.

## Net Income Per Share

Basic per share amounts are computed using the weighted-average number of common shares outstanding during the period. Dilutive per share amounts are computed using the weighted-average number of common shares outstanding and potentially dilutive securities, using the treasury stock method if their effect would be dilutive.

The following schedule reconciles the denominators of the Company's calculation for basic and diluted net income per share:

| (In thousands)  | Fiscal Years |        |        |
|---|--------------|--------|--------|
|   | 2018         | 2017   | 2016   |
| Shares used in basic per share computation            | 52,906       | 52,724 | 52,976 |
| Effect of dilutive common stock options outstanding   | 403          | 290    | 248    |
| Effect of unvested restricted stock units outstanding | 859          | 958    | 1,108  |
| Shares used in diluted per share computation          | 54,168       | 53,972 | 54,332 |

There were no equity awards excluded from the diluted per share calculation for fiscal years 2018, 2017 and 2016.

## Recently Adopted Accounting Pronouncements

On May 28, 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, *Revenue from Contracts with Customers*, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU replaced most existing revenue recognition guidance in U.S. generally accepted accounting principles (“GAAP”). The Company adopted the ASU as of the beginning of its first quarter of fiscal 2018 using the modified retrospective transition method. Under the modified retrospective transition method, the cumulative effect of applying the ASU is recognized at the date of initial application. The cumulative effect of adopting the ASU was not material and thus no cumulative effect adjustment was recorded. The Company’s analysis of its contracts under the ASU supports the recognition of revenue over time, which is consistent with the Company’s revenue recognition model prior to the adoption of the ASU.

There have been no other accounting pronouncements made effective during fiscal 2018 that have significance to the Company’s consolidated financial statements.

## Recent Accounting Pronouncements Not Yet Effective

In February 2016, the FASB established Topic 842, Leases, by issuing ASU No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use model (ROU) that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement.

The new standard is effective for the Company on December 29, 2018. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. The Company adopted the new standard on December 29, 2018 using the effective date as the date of initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before December 29, 2018.

The new standard provides a number of optional practical expedients in transition. The Company expects to elect the ‘package of practical expedients’, which permits it not to reassess under the new standard prior conclusions about lease identification, lease classification and initial direct costs.

The Company expects that this standard will have a material effect on its financial statements. While the Company continues to assess all of the effects of adoption, it currently believes the most significant effects relate to the recognition of new ROU assets and lease liabilities on its balance sheet for office and laboratory operating leases and providing significant new disclosures about its leasing activities. The Company is currently finalizing the completeness of the lease population and determining an applicable discount rate. The Company does not expect a significant change in its leasing activities between now and adoption.

#### Note 2: Revenue Recognition

Substantially all of the Company's engagements are performed under time and materials or fixed-price arrangements. For time and materials contracts, the Company utilizes the practical expedient under Accounting Standards Codification 606 – Revenue from Contracts with Customers, which states, if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity's performance completed to date (for example, a service contract in which an entity bills a fixed amount for each hour of service provided), the entity may recognize revenue in the amount to which the entity has a right to invoice. During 2018, the Company recognized revenue of \$312,772,000 associated with time and materials contracts. These revenues represent 82% of the Company's consolidated revenues and include revenues of \$243,085,000 for the Company's Engineering and Other Scientific segment and \$69,687,000 for the Company's Environmental and Health segment. The Company's time and materials contracts are terminable and subject to postponement or delay at any time by our clients, and as such, the performance obligations for all of the Company's time and materials contracts have an original expected duration of one year or less.

For fixed-price contracts the Company recognizes revenue over time because of the continuous transfer of control to the customer. The customer typically controls the work in process as evidenced either by contractual termination clauses or by the Company's rights to payment for work performed to date to deliver services that do not have an alternative use to the Company. Revenue for fixed-price contracts is recognized based on the relationship of incurred labor hours at standard rates to the Company's estimate of the total labor hours at standard rates it expects to incur over the term of the contract. The Company believes this methodology achieves a reliable measure of the revenue from the consulting services it provides to its customers under fixed-price contracts given the nature of the consulting services the Company provides and the following additional considerations:

- the Company considers labor hours at standard rates and expenses to be incurred when pricing its contracts;
  - the Company generally does not incur set up costs on its contracts;
- the Company does not believe that there are reliable milestones to measure progress towards completion;
  - the customer is required to pay the Company for time at standard rates plus materials incurred to date if the contract is terminated early;
  - the Company's contracts do not include award fees or bonuses;
- the Company does not include revenue for unpriced change orders until the customer agrees with the changes;
  - historically the Company has not had significant accounts receivable write-offs or cost overruns; and
  - the Company's contracts are typically progress billed on a monthly basis.

During 2018, the Company recognized revenue of \$66,751,000 associated with fixed-price contracts. These revenues represent 18% of the Company's consolidated revenues and include revenues of \$63,180,000 for the Company's Engineering and Other Scientific segment and \$3,571,000 for the Company's Environmental and Health segment. The Company's fixed-price contracts are terminable and subject to postponement or delay at any time by its clients, and as such, the performance obligations for all of the Company's fixed-price contracts have an original expected duration of one year or less.

Deferred revenues represent amounts billed to clients in advance of services provided. During 2018, \$6,067,000 of revenues were recognized that were included in the deferred revenue balance at December 29, 2017.

Reimbursements, including those related to travel and other out-of-pocket expenses, and other similar third party costs such as the cost of materials and certain subcontracts, are included in revenues, and an equivalent amount of reimbursable expenses are included in operating expenses. Any mark-up on reimbursable expenses is included in revenues before reimbursements. The Company reports revenues net of subcontractor fees for certain subcontracts where the Company has determined that it is acting as an agent because its performance obligation is to arrange for the provision of goods or services by another party. The total amount of subcontractor fees not included in revenues because the Company was acting as an agent were \$23,174,000 during 2018.

## Note 3: Cash, cash equivalents and short-term investments

Cash, cash equivalents and short-term investments consisted of the following as of December 28, 2018:

| (In thousands)  | Amortized<br>Cost | Unrealized<br>Gains | Unrealized<br>Losses | Estimated<br>Fair Value |
|---|-------------------|---------------------|----------------------|-------------------------|
| Classified as current assets:                           |                   |                     |                      |                         |
| Cash  | \$ 120,846        | \$ -                | \$ -                 | \$ 120,846              |
| Cash equivalents:                                       |                   |                     |                      |                         |
| Money market securities                                 | 6,213             | -                   | -                    | 6,213                   |
| Total cash equivalents                                  | 6,213             | -                   | -                    | 6,213                   |
| Total cash and cash equivalents                         | 127,059           | -                   | -                    | 127,059                 |
| Short-term investments:                                 |                   |                     |                      |                         |
| U.S. Treasury and agency securities                     | 81,634            | 91                  | (230 )               | 81,495                  |
| Total short-term investments                            | 81,634            | 91                  | (230 )               | 81,495                  |
| Total cash, cash equivalents and short-term investments | \$ 208,693        | \$ 91               | \$ (230 )            | \$ 208,554              |

Cash, cash equivalents and short-term investments consisted of the following as of December 29, 2017:

| (In thousands)  | Amortized<br>Cost | Unrealized<br>Gains | Unrealized<br>Losses | Estimated<br>Fair Value |
|---|-------------------|---------------------|----------------------|-------------------------|
| Classified as current assets:                           |                   |                     |                      |                         |
| Cash  | \$ 115,052        | \$ -                | \$ -                 | \$ 115,052              |
| Cash equivalents:                                       |                   |                     |                      |                         |
| Money market securities                                 | 9,742             | -                   | -                    | 9,742                   |
| Total cash equivalents                                  | 9,742             | -                   | -                    | 9,742                   |
| Total cash and cash equivalents                         | 124,794           | -                   | -                    | 124,794                 |
| Short-term investments:                                 |                   |                     |                      |                         |
| U.S. Treasury and agency securities                     | 71,997            | -                   | (393 )               | 71,604                  |
| Total short-term investments                            | 71,997            | -                   | (393 )               | 71,604                  |
| Total cash, cash equivalents and short-term investments | \$ 196,791        | \$ -                | \$ (393 )            | \$ 196,398              |





**Note 4: Fair Value Measurements**

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including available-for-sale fixed income securities, trading fixed income and equity securities held in its deferred compensation plan and the liability associated with its deferred compensation plan. There have been no transfers between fair value measurement levels during fiscal years 2018, 2017 and 2016. Any transfers between fair value measurement levels would be recorded on the actual date of the event or change in circumstances that caused the transfer. The fair value of these certain financial assets and liabilities was determined using the following inputs at December 28, 2018 (in thousands):

|   | Fair Value Measurements at Reporting Date Using |   |  |  |
|---|---|---|--|--|
|   | Total   | Quoted Prices<br>in<br>Active Markets<br>for<br>Identical Assets<br>(Level 1) | <b>Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</b> | Significant<br>Unobservable<br>Inputs<br>(Level 3) |
| <b>Assets</b>   |   |   |  |  |
| Money market securities <sup>(1)</sup>  | \$ 6,213  | \$ 6,213  | \$ -   | \$ -   |
| Fixed income available for sale securities <sup>(2)</sup>                         | 81,495  | -   | 81,495   | -  |
| Fixed income trading securities held in deferred compensation plan <sup>(3)</sup> | 18,618  | 18,618  | -  | -  |
| Equity trading securities held in deferred compensation plan <sup>(3)</sup>       | 39,160  | 39,160  | -  | -  |
| <b>Total</b>  | <b>\$ 145,486</b>                               | <b>\$ 63,991</b>  | <b>\$ 81,495</b>   | <b>\$ -</b>  |
| <b>Liabilities</b>  |   |   |  |  |
| Deferred compensation plan <sup>(4)</sup>   | 59,349  | 59,349  | -  | -  |
| <b>Total</b>  | <b>\$ 59,349</b>                                | <b>\$ 59,349</b>  | <b>\$ -</b>  | <b>\$ -</b>  |

<sup>(1)</sup> Included in cash and cash equivalents on the Company's consolidated balance sheet.

<sup>(2)</sup> Included in short-term investments on the Company's consolidated balance sheet.

<sup>(3)</sup> Included in other current assets and deferred compensation plan assets on the Company's consolidated balance sheet.

<sup>(4)</sup> Included in accrued liabilities and deferred compensation plan liabilities on the Company's consolidated balance sheet.



The fair value of these certain financial assets and liabilities was determined using the following inputs at December 29, 2017 (in thousands):

|   | Fair Value Measurements at Reporting Date Using |   |   |  |
|---|---|---|---|--|
|   | Total   | Quoted Prices<br>in<br>Active Markets<br>for<br>Identical Assets<br>(Level 1) | Significant<br>Other<br>Observable<br>Inputs<br>(Level 2) | Significant<br>Unobservable<br>Inputs<br>(Level 3) |
| <b>Assets</b>   |   |   |   |  |
| Money market securities <sup>(1)</sup>  | \$ 9,742  | \$ 9,742  | \$ -  | \$ -   |
| Fixed income available for sale securities <sup>(2)</sup>                         | 71,604  | -   | 71,604  | -  |
| Fixed income trading securities held in deferred compensation plan <sup>(3)</sup> | 13,686  | 13,686  | -   | -  |
| Equity trading securities held in deferred compensation plan <sup>(3)</sup>       | 39,664  | 39,664  | -   | -  |
| <b>Total</b>  | <b>\$ 134,696</b>                               | <b>\$ 63,092</b>  | <b>\$ 71,604</b>  | <b>\$ -</b>  |
| <b>Liabilities</b>  |   |   |   |  |
| Deferred compensation plan <sup>(4)</sup>   | 59,050  | 59,050  | -   | -  |
| <b>Total</b>  | <b>\$ 59,050</b>                                | <b>\$ 59,050</b>  | <b>\$ -</b>   | <b>\$ -</b>  |

(1) Included in cash and cash equivalents on the Company's consolidated balance sheet.

(2) Included in short-term investments on the Company's consolidated balance sheet.

(3) Included in other current assets and deferred compensation plan assets on the Company's consolidated balance sheet.

(4) Included in accrued liabilities and deferred compensation plan liabilities on the Company's consolidated balance sheet.

Fixed income available-for-sale securities as of December 28, 2018 and December 29, 2017 represent primarily obligations of the United States Treasury and other United States agencies. Fixed income and equity trading securities represent mutual funds held in the Company's deferred compensation plan. See Note 11 for additional information about the Company's deferred compensation plan.

The following table summarizes the cost and estimated fair value of short-term fixed income securities classified as short-term investments based on remaining effective maturities as of December 28, 2018:

| (In thousands)                | Amortized<br>Cost | Estimated<br>Fair Value |
|-------------------------------|-------------------|-------------------------|
| Due within one year           | \$ 32,986         | \$ 32,826               |
| Due between one and two years | 48,648            | 48,669                  |
| Total                         | \$ 81,634         | \$ 81,495               |

At December 28, 2018 and December 29, 2017, the Company did not have any assets or liabilities valued using significant unobservable inputs.

The following financial instruments are not measured at fair value on the Company's consolidated balance sheet at December 28, 2018, but require disclosure of their fair values: accounts receivable, other assets and accounts payable. The estimated fair value of such instruments at December 28, 2018 approximates their carrying value as reported on the consolidated balance sheet.

There were no other-than-temporary impairments or credit losses related to available-for-sale securities during fiscal years 2018, 2017 and 2016.

#### Note 5: Property, Equipment and Leasehold Improvements

| (In thousands)                                      | Fiscal Years |           |
|---|--------------|-----------|
|   | 2018         | 2017      |
| Property:   |              |           |
| Land  | \$ 17,103    | \$ 11,888 |
| Buildings   | 38,946       | 38,112    |
| Construction in progress                            | 6,508        | 632       |
| Equipment:  |              |           |
| Machinery and equipment                             | 46,492       | 42,803    |
| Office furniture and equipment                      | 10,352       | 9,911     |
| Leasehold improvements                              | 15,621       | 15,178    |
|   | 135,022      | 118,524   |
| Less accumulated depreciation and amortization      | 88,919       | 83,510    |
| Property, equipment and leasehold improvements, net | \$ 46,103    | \$ 35,014 |

Depreciation and amortization for fiscal years 2018, 2017 and 2016 was \$6,292,000, \$6,285,000 and \$6,131,000, respectively.

## Note 6: Other Significant Balance Sheet Components

## Account receivable, net

| (In thousands)                                      | Fiscal Years |           |
|---|--------------|-----------|
|   | 2018         | 2017      |
| Billed accounts receivable                          | \$73,905     | \$78,139  |
| Unbilled accounts receivable                        | 35,975       | 35,487    |
| Allowance for contract losses and doubtful accounts | (4,066 )     | (3,526 )  |
| Total accounts receivable, net                      | \$105,814    | \$110,100 |

## Accounts payable and accrued liabilities

| (In thousands)                                       | Fiscal Years |          |
|--|--------------|----------|
|  | 2018         | 2017     |
| Accounts payable                                     | \$2,551      | \$2,784  |
| Accrued liabilities                                  | 9,732        | 11,957   |
| Total accounts payable and other accrued liabilities | \$12,283     | \$14,741 |

## Accrued payroll and employee benefits

| (In thousands)                              | Fiscal Years |          |
|---|--------------|----------|
|   | 2018         | 2017     |
| Accrued bonuses payable                     | \$49,436     | \$44,752 |
| Accrued 401(k) contributions                | 8,154        | 7,691    |
| Accrued vacation                            | 10,390       | 9,707    |
| Deferred compensation plan                  | 6,641        | 6,274    |
| Other accrued payroll and employee benefits | 2,234        | 1,640    |
| Total accrued payroll and employee benefits | \$76,855     | \$70,064 |

Other accrued payroll and employee benefits consist primarily of accrued wages, payroll taxes and disability insurance programs. A portion of accrued bonuses payable will be settled by issuing fully vested restricted stock units. See Note 9 and Note 15 for additional information.

**Note 7: Income Taxes**

Income before income taxes includes income from foreign operations of \$8,005,000, \$7,707,000 and \$5,616,000 for fiscal years 2018, 2017 and 2016, respectively.

Total income tax expense for fiscal years 2018, 2017 and 2016 consisted of the following:

|                | Fiscal Years |          |          |
|----------------|--------------|----------|----------|
| (In thousands) | 2018         | 2017     | 2016     |
| Current        |              |          |          |
| Federal        | \$16,487     | \$22,821 | \$18,877 |
| Foreign        | 1,624        | 1,514    | 1,085    |
| State          | 6,667        | 5,083    | 4,282    |
|                | 24,778       | 29,418   | 24,244   |
| Deferred       |              |          |          |
| Federal        | (2,604 )     | 12,570   | (2,047 ) |
| State          | (1,111 )     | (784 )   | (555 )   |
|                | (3,715 )     | 11,786   | (2,602 ) |
| Total          | \$21,063     | \$41,204 | \$21,642 |

The Company's effective tax rate differs from the statutory federal tax rate of 21% for 2018 and 35% for 2017 and 2016 as shown in the following schedule:

|  | Fiscal Years |          |          |
|--|--------------|----------|----------|
| (In thousands)   | 2018         | 2017     | 2016     |
| Tax at federal statutory rate  | \$19,597     | \$28,878 | \$24,193 |
| Re-measurement of deferred tax assets to lower enacted domestic tax rate | -            | 15,137   | -        |
| Mandatory repatriation of foreign earnings                               | -            | 1,370    | -        |
| State taxes, net of federal benefit                                      | 4,391        | 2,806    | 2,423    |
| Non-deductible expenses  | 335          | 417      | 274      |
| Non-deductible stock-based compensation                                  | 20           | 18       | 11       |
| Excess tax benefit from equity incentive plans                           | (3,310 )     | (5,831 ) | (4,321 ) |
| Difference between statutory rate and foreign effective tax rate         | (217 )       | (1,339 ) | (889 )   |
| Other  | 247          | (252 )   | (49 )    |
| Tax expense  | \$21,063     | \$41,204 | \$21,642 |
| Effective tax rate   | 22.6 %       | 49.9 %   | 31.3 %   |





The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 28, 2018 and December 29, 2017 are presented in the following schedule:

| (In thousands)                                       | Fiscal Years |           |
|--|--------------|-----------|
|  | 2018         | 2017      |
| Deferred tax assets:                                 |              |           |
| Accrued liabilities and allowances                   | \$ 13,964    | \$ 13,265 |
| Deferred compensation plan                           | 22,944       | 22,297    |
| Property, equipment and leasehold improvements       | 192          | 288       |
| Unrealized loss on deferred compensation plan assets | 320          | -         |
| Other  | 34           | 98        |
| Total deferred tax assets                            | 37,454       | 35,948    |
| Deferred tax liabilities:                            |              |           |
| State taxes  | (1,184 )     | (1,232 )  |
| Deductible goodwill                                  | (2,086 )     | (2,078 )  |
| Property, equipment and leasehold improvements       | -            | -         |
| Unrealized gain of deferred compensation plan assets | -            | (2,119 )  |
| Other  | (94 )        | (82 )     |
| Total deferred tax liabilities                       | (3,364 )     | (5,511 )  |
| Net deferred tax assets                              | \$34,090     | \$30,437  |

Management believes it is more likely than not that the results of future operations will generate sufficient taxable income to realize the net deferred tax assets.

The Tax Cuts and Jobs Act (Tax Legislation) was enacted on December 22, 2017 and lowers U.S. corporate income tax rates as of January 1, 2018, implements a territorial tax system and imposes a repatriation tax on deemed repatriated earnings of foreign subsidiaries. The impact of the Tax Legislation to the Company was an increase in income tax expense of \$16,507,000 during 2017. The Company's deferred tax assets were re-measured at the lower enacted corporate tax rate of 21% which contributed \$15,137,000 to the 2017 increase in income tax expense associated with the Tax Legislation. The Company also has foreign earnings that were subject to the mandatory repatriation tax. The total mandatory repatriation tax, net of the benefit of the Company's foreign tax credits, contributed \$1,370,000 to the 2017 increase in income tax expense associated with the Tax Legislation. The Company elected to pay the mandatory repatriation tax over a period of eight years.

The Tax Legislation also includes a provision to tax global intangible low-taxed income ("GILTI") of foreign subsidiaries. An accounting policy election is available to either account for the tax effects of GILTI in the period that is subject to such taxes or to provide deferred taxes for book and tax basis differences that upon reversal may be subject to such taxes. The Company has elected to account for the tax effects of GILTI in the period that it is subject

to such tax.

The Company is entitled to a deduction for federal and state tax purposes with respect to employees' stock award activity. The net deduction in taxes otherwise payable arising from that deduction has been recorded as an income tax benefit. For fiscal years 2018, 2017 and 2016, the net deduction in tax payable arising from employees' stock award activity was \$4,154,000, \$6,528,000 and \$4,827,000, respectively.

The Company and its subsidiaries file income tax returns in the United States federal jurisdiction, California and various other state and foreign jurisdictions. The Company is no longer subject to United States federal income tax examination for years prior to 2015. The Company is no longer subject to California franchise tax examinations for years prior to 2014. With few exceptions, the Company is no longer subject to state and local or non-United States income tax examination by tax authorities for years prior to 2014.

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

|  |             |
|--|-------------|
| Balance at December 30, 2016                                 | \$1,956,000 |
| Additions based on tax positions related to the current year | 597,000     |
| Additions for tax positions of prior years                   | 11,000      |
| Reductions due to lapse of statute of limitations            | (338,000 )  |
| Reductions for tax positions of prior years                  | (437,000 )  |
| Settlements  | -           |
| Balance at December 29, 2017                                 | \$1,789,000 |
| Additions based on tax positions related to the current year | 599,000     |
| Additions for tax positions of prior years                   | -           |
| Reductions due to lapse of statute of limitations            | (257,000 )  |
| Reductions for tax positions of prior years                  | (383,000 )  |
| Settlements  | -           |
| Balance at December 28, 2018                                 | \$1,748,000 |

Unrecognized tax benefits are included in other liabilities in the accompanying balance sheet. To the extent these unrecognized tax benefits are ultimately recognized, they will impact the effective tax rate by \$1,423,000 in a future period. There are no uncertain tax positions whose resolution in the next 12 months is expected to materially affect operating results.

## Note 8: Stockholders' Equity

**Preferred Stock**

The Company has authorized 2,000,000 shares of undesignated preferred stock with a par value of \$0.001 per share. None of the preferred shares were issued and outstanding at December 28, 2018 and December 29, 2017.

**Dividends**

The Company declared and paid cash dividends per common share during the periods presented as follows:

|                | Fiscal Year 2018 |                |
|----------------|------------------|----------------|
|                | Dividend         | Amount         |
|                | Per              | (in thousands) |
|                | Share            |                |
| First Quarter  | \$0.13           | \$ 6,700       |
| Second Quarter | \$0.13           | 6,764          |
| Third Quarter  | \$0.13           | 6,765          |
| Fourth Quarter | \$0.13           | 6,723          |
|                |                  | \$ 26,952      |

|                | Fiscal Year 2017 |                |
|----------------|------------------|----------------|
|                | Dividend         | Amount         |
|                | Per              | (in thousands) |
|                | Share            |                |
| First Quarter  | \$0.105          | \$ 5,374       |
| Second Quarter | \$0.105          | 5,424          |
| Third Quarter  | \$0.105          | 5,424          |
| Fourth Quarter | \$0.105          | 5,416          |
|                |                  | \$ 21,638      |

On January 31, 2019, the Company's Board of Directors announced a cash dividend of \$0.16 per share of the Company's common stock, payable March 22, 2019, to stockholders of record as of March 8, 2019. The Company expects to continue paying quarterly dividends in the future, subject to declaration by the Company's Board of Directors.

## **Treasury Stock**

Net losses related to the re-issuance of treasury stock to settle restricted stock unit and stock option awards of \$5,892,000, \$5,667,000 and \$5,791,000 were recorded as a reduction to retained earnings during 2018, 2017 and 2016, respectively.

## **Repurchase of Common Stock**

The Company repurchased 562,000 shares of its common stock for \$27,915,000 during 2018. The Company repurchased 372,000 shares of its common stock for \$11,931,000 during 2017. The Company repurchased 982,000 shares of its common stock for \$24,456,000 during 2016. On October 18, 2016 the Board of Directors authorized \$35,000,000 for the repurchase of Exponent's common stock. On October 20, 2015 the Board of Directors authorized \$35,000,000 for the repurchase of Exponent's common stock. These repurchase programs have no expiration dates. As of December 28, 2018, the Company had remaining authorization under its stock repurchase plan of \$17,462,000 to repurchase shares of common stock.

## **Note 9: Stock-Based Compensation**

On May 29, 2008, the Company's stockholders approved the 2008 Equity Incentive Plan and the 2008 Employee Stock Purchase Plan ("ESPP"). The 2008 Equity Incentive Plan and ESPP were previously adopted by the Company's Board of Directors on April 8, 2008, subject to stockholder approval.

The 2008 Equity Incentive Plan allows for the award of stock options, stock awards (including stock units, stock grants and stock appreciation rights or other similar equity awards) and cash awards to officers, employees, consultants and non-employee members of the Board of Directors. The total number of shares reserved for issuance under the 2008 Equity Incentive Plan was 11,856,300 shares of common stock, subject to adjustment resulting from a stock split or the payment of a stock dividend or any other increase or decrease in the number of issued shares of the Company's stock effected without receipt of consideration by the Company. As of December 28, 2018, 2,472,419 shares were available for grant under the 2008 Equity Incentive Plan.

The ESPP allows for officers and employees to purchase common stock through payroll deductions of up to 15% of a participant's eligible compensation. Shares of common stock are purchased under the ESPP at 95% of the fair market value of the Company's common stock on each purchase date. Subject to adjustment resulting from a stock split or the payment of a stock dividend or any other increase or decrease in the number of issued shares of the Company's stock effected without receipt of consideration by the Company, the total number of shares reserved for issuance under the

Edgar Filing: EXPONENT INC - Form 10-K

ESPP was 1,200,000 shares of common stock. As of December 28, 2018, 414,275 shares were available for grant. Weighted average purchase prices for shares sold under the ESPP plan in fiscal 2018, 2017 and 2016 were \$45.26, \$30.67 and \$25.99, respectively.

## Restricted Stock Units

The Company grants restricted stock units to employees and outside directors. These restricted stock unit grants are designed to attract and retain employees, and to better align employee interests with those of the Company's stockholders. For a select group of employees, up to 40% of their annual bonus is settled with fully vested restricted stock unit awards. Under these fully vested restricted stock unit awards, the holder of each award has the right to receive one share of the Company's common stock for each fully vested restricted stock unit four years from the date of grant. Each individual who received a fully vested restricted stock unit award is granted a matching number of unvested restricted stock unit awards. These unvested restricted stock unit awards cliff vest four years from the date of grant, at which time the holder of each award will have the right to receive one share of the Company's common stock for each restricted stock unit award, provided the holder of each award has met certain employment conditions. In the case of retirement at 59 ½ years or older, all unvested restricted stock unit awards will continue to vest provided the holder of each award does all consulting work through the Company and does not become an employee for a past or present client, beneficial party or competitor of the Company.

All restricted stock units granted have dividend equivalent rights ("DER"), which entitle holders of restricted stock units to the same dividend value per share as holders of common stock. DER are subject to the same vesting and other terms and conditions as the corresponding unvested restricted stock units. DER are accumulated and paid when the underlying shares vest and are forfeited if the underlying shares are forfeited.

The value of these restricted stock unit awards is determined based on the market price of the Company's common stock on the date of grant. The value of fully vested restricted stock unit awards issued is recorded as a reduction to accrued bonuses. The portion of bonus expense that the Company expects to settle with fully vested restricted stock unit awards is recorded as stock-based compensation during the period the bonus is earned. For 2018, 2017 and 2016, the Company recorded stock-based compensation expense associated with accrued bonus awards of \$8,443,000, \$8,331,000 and \$6,181,000, respectively.

The Company recorded stock-based compensation expense associated with the unvested restricted stock unit awards of \$7,653,000, \$7,075,000 and \$6,583,000 during 2018, 2017 and 2016, respectively. The total fair value of restricted stock unit awards vested during 2018, 2017, and 2016 was \$23.2 million, \$21.3 million and \$18.5 million, respectively. The weighted-average grant date fair values of restricted stock unit awards granted during 2018, 2017 and 2016 were \$40.61, \$29.50 and \$24.14, respectively.

The number of unvested restricted stock unit awards outstanding as of December 28, 2018 is as follows <sup>(1)</sup>:

Edgar Filing: EXPONENT INC - Form 10-K

|                                 | Number of awards outstanding | Weighted-average grant date fair value | Weighted-average remaining contractual term (years) | Aggregate intrinsic value (in thousands) <sup>(2)</sup> |
|---------------------------------|------------------------------|--|---|---|
| Balance as of December 29, 2017 | 1,185,184                    | \$ 22.96                               |   |   |
| Awards granted                  | 421,463                      | 40.61                                  |   |   |
| Awards vested                   | (571,257 )                   | 27.28                                  |   |   |
| Awards forfeited                | (851 )                       | 24.60                                  |   |   |
| Balance as of December 28, 2018 | 1,034,539                    | \$ 27.76                               | 1.6   | \$ 51,644   |

<sup>(1)</sup> Does not include employee stock purchase plans or stock option plans.

<sup>(2)</sup> The intrinsic value is calculated as the market value as of the end of the fiscal period. As reported by the NASDAQ Global Select Market, the market value as of December 28, 2018 was \$49.92.

#### Stock Options

The Company currently grants stock options under the 2008 Equity Incentive Plan. Options are granted for terms of ten years and generally vest ratably over a four-year period from the grant date. The Company grants options at exercise prices equal to the fair value of the Company's common stock on the date of grant. All stock options have dividend equivalent rights, which entitle holders of stock options to the same dividend value per share as holders of common stock. DER are subject to the same vesting terms as the corresponding stock options. DER are accumulated and paid in cash when the underlying stock options vest and are forfeited if the underlying stock options do not vest. During 2018, 2017 and 2016, the Company recorded stock-based compensation expense of \$897,000, \$749,000 and \$569,000, respectively, associated with stock options.

Option activity is as follows <sup>(1)</sup>:

|                                  | Number<br>of shares<br>outstanding | Weighted-<br>average<br>exercise<br>price | Weighted-average<br>remaining<br>contractual<br>term (years) | Aggregate<br>intrinsic value<br>(in thousands) |
|----------------------------------|------------------------------------|---|--|--|
| Balance as of December 29, 2017  | 680,000                            | \$ 18.39                                  |  |  |
| Options granted                  | 98,000                             | 37.45                                     |  |  |
| Options forfeited and expired    | -                                  | -   |  |  |
| Options exercised                | -                                  | -   |  |  |
| Balance as of December 28, 2018  | 778,000                            | \$ 20.80                                  | 5.73   | \$ 22,659                                      |
| Exercisable at December 28, 2018 | 512,000                            | \$ 15.76                                  | 4.47   | \$ 17,488                                      |

(1) Does not include restricted stock or employee stock purchase plans.

The total intrinsic value of options exercised during 2018, 2017 and 2016 was \$0, \$1,461,000, and \$999,000, respectively. The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the Company's closing stock price on the last trading day of the fiscal year ended December 28, 2018, and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 28, 2018. This amount changes based on the fair-value of the Company's stock.

The Company uses the Black-Scholes option-pricing model to determine the fair value of options granted. The determination of the fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by the Company's stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the award, actual and projected employee stock option exercise behaviors, the risk-free interest rate and expected dividends.

The Company used historical exercise and post-vesting forfeiture and expiration data to estimate the expected term of options granted. The historical volatility of the Company's common stock over a period of time equal to the expected term of the options granted was used to estimate expected volatility. The risk-free interest rate used in the option-pricing model was based on United States Treasury zero coupon issues with remaining terms similar to the expected term on the options. The dividend yield assumption considers the expectation of continued declaration of dividends, offset by option holders' dividend equivalent rights. All share-based payment awards are recognized on a straight-line basis over the requisite service periods of the awards.



The assumptions used to value option grants for 2018, 2017 and 2016 are as follows:

|                          | Stock Option Plan |       |       |
|--------------------------|-------------------|-------|-------|
|                          | 2018              | 2017  | 2016  |
| Expected term (in years) | 5.9               | 5.9   | 6.0   |
| Risk-free interest rate  | 2.74%             | 2.11% | 1.28% |
| Volatility               | 23 %              | 24 %  | 25 %  |
| Dividend yield           | 0 %               | 0 %   | 0 %   |

The weighted-average grant date fair value of options granted during 2018, 2017 and 2016 were \$10.59, \$8.09 and \$6.54, respectively.

The amount of stock-based compensation expense and the related income tax benefit recognized in the Company's consolidated statements of income for 2018, 2017 and 2016 is as follows:

|  | 2018      | 2017      | 2016      |
|--|-----------|-----------|-----------|
| <b>(In thousands)</b>                  |           |           |           |
| Compensation and related expenses:     |           |           |           |
| Restricted stock units                 | \$ 15,561 | \$ 14,809 | \$ 12,225 |
| Stock option grants                    | 897       | 749       | 569       |
| Sub-total                              | 16,458    | 15,558    | 12,794    |
| General and administrative expenses:   |           |           |           |
| Restricted stock units                 | 535       | 597       | 539       |
| Sub-total                              | 535       | 597       | 539       |
| Total stock-based compensation expense | \$ 16,993 | \$ 16,155 | \$ 13,333 |
| Income tax benefit                     | \$ 4,467  | \$ 6,331  | \$ 5,214  |

As of December 28, 2018, there was \$8,681,000 of unrecognized compensation cost, expected to be recognized over a weighted average period of 2.5 years, related to unvested restricted stock unit awards and \$931,000 of unrecognized compensation cost, expected to be recognized over a weighted average period of 2.5 years, related to unvested stock options.

#### Note 10: Retirement Plans

The Company provides a defined contribution retirement plan for its employees whereby the Company contributes to each eligible employee's account 7% of the employee's eligible base salary plus overtime. The employee does not need to make a contribution to the plan to be eligible for the Company's 7% contribution. To be eligible under the plan, an employee must be at least 21 years of age and be either a full-time or part-time salaried employee. The 7% Company contribution will vest 20% per year for the first 5 years of employment and then immediately thereafter. The Company's expenses related to this plan were \$8,419,000, \$7,914,000, and \$7,761,000 in 2018, 2017, and 2016, respectively.

#### Note 11: Deferred Compensation Plans

The Company maintains nonqualified deferred compensation plans for the benefit of a select group of highly compensated employees. Under these plans, participants may elect to defer up to 100% of their compensation.

Company assets that are earmarked to pay benefits under the plans are held in a rabbi trust and are subject to the claims of the Company's creditors. As of December 28, 2018 and December 29, 2017 the invested amounts under the plans totaled \$57,778,000 and \$53,350,000, respectively. These assets are classified as trading securities and are recorded at fair market value with changes recorded as adjustments to other income.

As of December 28, 2018 and December 29, 2017, vested amounts due under the plans totaled \$59,349,000 and \$59,050,000, respectively. Changes in the liability are recorded as adjustments to compensation expense. During fiscal years 2018, 2017 and 2016, the Company recognized compensation expense of (\$3,900,000), \$6,547,000, and \$3,861,000, respectively, as a result of changes in the market value of the trust assets with the same amount being recorded as other income.

**Note 12: Commitments and Contingencies**

The following is a summary of the future minimum payments, required under non-cancelable operating leases, with terms in excess of one year, as of December 28, 2018:

(In thousands)

| Fiscal year | Lease commitments |
|-------------|-------------------|
| 2019        | \$ 7,220          |
| 2020        | 5,988             |
| 2021        | 4,940             |
| 2022        | 3,887             |
| 2023        | 2,600             |
| Thereafter  | 6,157             |
|             | \$ 30,792         |

Total rent expense from property leases in fiscal 2018, 2017, and 2016 was \$7,488,000, \$6,712,000 and \$6,478,000, respectively. The Company had \$12,315,000 in outstanding purchase commitments as of December 28, 2018, which includes \$11,769,000 associated with the construction of our office and laboratory facilities in Natick, Massachusetts. These commitments are expected to be fulfilled by the end of fiscal 2019.

The Company is a party to various legal actions from time to time and may be contingently liable in connection with claims and contracts arising in the normal course of business, the outcome of which the Company believes, after consultation with legal counsel, will not have a material adverse effect on its financial condition, results of operations or liquidity. However, due to the risks and uncertainties inherent in legal proceedings, actual results could differ from current expected results. All legal costs associated with litigation are expensed as incurred.

#### Note 13: Miscellaneous Income, Net

Miscellaneous income, net, consisted of the following:

| (In thousands)                                   | Fiscal Years |         |         |
|--|--------------|---------|---------|
|  | 2018         | 2017    | 2016    |
| Rental income                                    | 2,823        | 2,655   | 2,435   |
| Gain (loss) on deferred compensation investments | (3,900)      | 6,547   | 3,861   |
| Gain (loss) on foreign exchange                  | 167          | (19 )   | 224     |
| Other  | 20           | (19 )   | 8       |
| Total  | \$(890 )     | \$9,164 | \$6,528 |

#### Note 14: Industry and Client Credit Risk

The Company serves clients in various segments of the economy. During fiscal 2018, the Company provided services representing approximately 27% of revenues to clients in the consumer products industry. During fiscal 2018, the Company provided services representing approximately 16% of revenues to clients in the transportation industry. During fiscal 2018, the Company provided services representing approximately 15% of revenues to clients in the energy and utilities industries.

One client comprised 12% of the Company's revenues during 2018. The same client comprised 14% of the Company's revenues during 2017. No other single client comprised more than 10% of the Company's revenues during 2018 or 2017. No single client comprised more than 10% of the Company's revenues during 2016. No single client comprised

more than 10% of the Company's accounts receivable at December 28, 2018. One client comprised 24% of the Company's accounts receivable at December 29, 2017. No other single client comprised more than 10% of the Company's accounts receivable at December 29, 2017.

**Note 15: Supplemental Cash Flow Information**

The following is supplemental disclosure of cash flow information:

| (In thousands)   | Fiscal Years |          |          |
|--|--------------|----------|----------|
|  | 2018         | 2017     | 2016     |
| Cash paid during the year:                               |              |          |          |
| Income taxes   | \$28,636     | \$25,849 | \$22,280 |
| Non-cash investing and financing activities:             |              |          |          |
| Unrealized gain (loss) on investments                    | \$191        | \$(90 )  | \$(81 )  |
| Vested stock unit awards granted to settle accrued bonus | \$7,643      | \$6,910  | \$6,334  |
| Accrual for capital expenditures                         | \$1,231      | \$148    | \$284    |

**Note 16: Segment Reporting**

The Company has two reportable operating segments based on two primary areas of service. The Engineering and Other Scientific segment is a broad service group providing technical consulting in different practices primarily in engineering. The Environmental and Health segment provides services in the area of environmental, epidemiology and health risk analysis. This segment provides a wide range of consulting services relating to environmental hazards and risks and the impact on both human health and the environment.

Segment information is presented for selected data from the statements of income and statements of cash flows for fiscal years 2018, 2017 and 2016. Segment information for selected data from the balance sheets is presented for the fiscal years ended December 28, 2018 and December 29, 2017. Our CEO, the chief operating decision maker, does not review total assets in her evaluation of segment performance and capital allocation.

**Revenues**

| (In thousands)                   | Fiscal Years |           |           |
|----------------------------------|--------------|-----------|-----------|
|                                  | 2018         | 2017      | 2016      |
| Engineering and Other Scientific | \$306,265    | \$277,603 | \$248,297 |
| Environmental and Health         | 73,258       | 70,196    | 66,779    |
| Total revenues                   | \$379,523    | \$347,799 | \$315,076 |

**Operating Income**

| (In thousands)                   | Fiscal Years |           |          |
|----------------------------------|--------------|-----------|----------|
|                                  | 2018         | 2017      | 2016     |
| Engineering and Other Scientific | \$100,307    | \$93,451  | \$80,494 |
| Environmental and Health         | 23,824       | 22,340    | 18,650   |
| Total segment operating income   | 124,131      | 115,791   | 99,144   |
| Corporate operating expense      | (32,675 )    | (43,740 ) | (37,233) |
| Total operating income           | \$91,456     | \$72,051  | \$61,911 |

**Capital Expenditures**

| (In thousands)                     | Fiscal Years |         |          |
|------------------------------------|--------------|---------|----------|
|                                    | 2018         | 2017    | 2016     |
| Engineering and Other Scientific   | \$4,528      | \$3,648 | \$4,309  |
| Environmental and Health           | 199          | 218     | 124      |
| Total segment capital expenditures | 4,727        | 3,866   | 4,433    |
| Corporate capital expenditures     | 12,654       | 859     | 9,960    |
| Total capital expenditures         | \$17,381     | \$4,725 | \$14,393 |

**Depreciation and Amortization**

| (In thousands)                              | Fiscal Years |         |         |
|---|--------------|---------|---------|
|   | 2018         | 2017    | 2016    |
| Engineering and Other Scientific            | \$4,435      | \$4,449 | \$4,429 |
| Environmental and Health                    | 171          | 179     | 181     |
| Total segment depreciation and amortization | 4,606        | 4,628   | 4,610   |
| Corporate depreciation and amortization     | 1,686        | 1,657   | 1,521   |
| Total depreciation and amortization         | \$6,292      | \$6,285 | \$6,131 |

Information regarding the Company's operations in different geographical areas:

**Property, Equipment and Leasehold Improvements, net**

| (In thousands)    | Fiscal Years |          |
|-------------------|--------------|----------|
|                   | 2018         | 2017     |
| United States     | \$44,181     | \$33,771 |
| Foreign Countries | 1,922        | 1,243    |
| Total             | \$46,103     | \$35,014 |

**Revenues <sup>(1)</sup>**

| (In thousands)    | Fiscal Years |           |           |
|-------------------|--------------|-----------|-----------|
|                   | 2018         | 2017      | 2016      |
| United States     | \$334,422    | \$308,406 | \$281,223 |
| Foreign Countries | 45,101       | 39,393    | 33,853    |
| Total             | \$379,523    | \$347,799 | \$315,076 |

<sup>(1)</sup> Geographic revenues are allocated based on the location of the client.

Edgar Filing: EXPONENT INC - Form 10-K

Below is a breakdown of goodwill, reported by segment as of December 28, 2018 and December 29, 2017:

| (In thousands) | Environmental<br>and Health | Engineering and<br>Other Scientific | Total   |
|----------------|-----------------------------|-------------------------------------|---------|
| Goodwill       | \$ 8,099                    | \$ 508                              | \$8,607 |

There were no changes in the carrying amount of goodwill for 2018, 2017 and 2016. There were no goodwill impairments or gains or losses on disposals for any portion of the Company's reporting units during 2018, 2017 and 2016.



**Note 17: Related Party Transactions**

Debra Zumwalt currently serves on the Company's Board of Directors. Ms. Zumwalt is the Vice President and General Counsel for Stanford University. During the year ended December 28, 2018, the Company performed consulting services for Stanford University and recorded revenue of approximately \$1.5 million.

**Note 18: Subsequent Event**

On January 31, 2019, the Company announced that its Board of Directors has declared a quarterly cash dividend of \$0.16 per share to be paid on March 22, 2019 to all common stockholders of record as of March 8, 2019. The Board of Directors also authorized an additional \$75 million for share repurchases.

On January 29<sup>th</sup> 2019, PG&E Corp. ("PG&E") filed for bankruptcy under chapter 11 of the U.S. bankruptcy code. The Company's total outstanding accounts receivable from PG&E as of December 28, 2018 was \$5.6 million of which \$2.1 million was paid during fiscal 2019 prior to the bankruptcy filing date. The Company continued to do work for PG&E during fiscal 2019 and the total outstanding accounts receivable from PG&E on the bankruptcy filing date of January 29, 2019 was \$6.0 million. Due to the uncertainties associated with the bankruptcy process the Company believes that an impairment of the receivable is reasonably possible, however it is unable to estimate the amount of this receivable that will ultimately be collected. As such, the Company has not recorded an impairment charge related to this asset, but will do so once an impairment, if any, is determined to be probable and estimable.

**Comparative Quarterly Financial Data (unaudited)**

Summarized quarterly financial data is as follows:

| Fiscal 2018<br>(In thousands, except per share data) | March 30,<br>2018 | June 29,<br>2018 | September 28,<br>2018 | December 28,<br>2018      |
|--|-------------------|------------------|-----------------------|---------------------------|
| Revenues before reimbursements                       | \$ 90,684         | \$ 89,972        | \$ 88,714             | \$ 85,269                 |
| Revenues   | 96,457            | 95,621           | 95,302                | 92,143                    |
| Operating income                                     | 21,598            | 22,478           | 20,594                | 26,786                    |
| Income before income taxes                           | 22,450            | 24,919           | 23,989                | 21,959                    |
| Net income   | \$ 20,340         | \$ 18,425        | \$ 17,453             | \$ 16,036                 |
| Net income per share                                 |                   |                  |                       |                           |
| Basic  | \$ 0.39           | \$ 0.35          | \$ 0.33               | \$ 0.30                   |
| Diluted  | \$ 0.38           | \$ 0.34          | \$ 0.32               | \$ 0.30                   |
| Shares used in per share computations                |                   |                  |                       |                           |
| Basic  | 52,744            | 53,008           | 53,032                | 52,839                    |
| Diluted  | 54,012            | 54,195           | 54,302                | 54,119                    |
| <br>   |                   |                  |                       |                           |
| Fiscal 2017<br>(In thousands, except per share data) | March 31,<br>2017 | June 30,<br>2017 | September 29,<br>2017 | December 29,<br>2017      |
| Revenues before reimbursements                       | \$ 80,467         | \$ 84,120        | \$ 82,359             | \$ 82,718                 |
| Revenues   | 84,122            | 87,840           | 87,555                | 88,282                    |
| Operating income                                     | 14,634            | 20,317           | 19,305                | 17,795                    |
| Income before income taxes                           | 17,410            | 22,348           | 22,030                | 20,721                    |
| Net income (loss)                                    | \$ 16,576         | \$ 13,791        | \$ 14,643             | \$ (3,705) <sup>(1)</sup> |
| Net income per share                                 |                   |                  |                       |                           |
| Basic  | \$ 0.32           | \$ 0.26          | \$ 0.28               | \$(0.07 )                 |
| Diluted  | \$ 0.31           | \$ 0.26          | \$ 0.27               | \$(0.07 )                 |
| Shares used in per share computations                |                   |                  |                       |                           |
| Basic  | 52,604            | 52,830           | 52,740                | 52,726                    |
| Diluted  | 53,962            | 53,936           | 53,926                | 52,726                    |

<sup>(1)</sup> The decrease in net income and diluted earnings per share during the fourth quarter of 2017 was due to the impact of the tax legislation. During the fourth quarter of 2017, the Company recorded a tax expense of \$16,507,000 related to the tax legislation signed into law during the fourth quarter of 2017. The Company has domestic deferred

tax assets primarily associated with its deferred compensation plan and stock-based compensation program, which were previously valued at the federal corporate income tax rate of 35%. The Company's deferred tax assets were re-measured at the lower enacted corporate tax rate of 21% which contributed \$15,137,000 to the increase in income tax associated with the tax legislation. The Company also has foreign earnings that were subject to the mandatory repatriation tax. The total mandatory repatriation tax, net of the benefit of its foreign tax credits, contributed \$1,370,000 to the increase in income tax expense associated with the tax legislation.

**Schedule II****Valuation and Qualifying Accounts**

|                               | Balance at<br>Beginning of<br>Year | Additions                              |                                     | Deletions <sup>(1)</sup>                        |   | Balance<br>at End of<br>Year |
|-------------------------------|------------------------------------|--|-------------------------------------|---|---|------------------------------|
|                               |                                    | Provision<br>Charged<br>to<br>Expenses | Provision<br>Charged to<br>Revenues | Accounts<br>Written-off<br>Net of<br>Recoveries |   |                              |
| (In thousands)                |                                    |  |                                     |   |   |                              |
| Year Ended December 28, 2018  |                                    |  |                                     |   |   |                              |
| Allowance for bad debt        | \$ 917                             | \$293                                  | \$ -                                | \$ (363   | ) | \$ 847                       |
| Allowance for contract losses | \$ 2,609                           | \$-                                    | \$ 1,940                            | \$ (1,330                                       | ) | \$ 3,219                     |
| Year Ended December 29, 2017  |                                    |  |                                     |   |   |                              |
| Allowance for bad debt        | \$ 923                             | \$473                                  | \$ -                                | \$ (479   | ) | \$ 917                       |
| Allowance for contract losses | \$ 2,494                           | \$-                                    | \$ 2,033                            | \$ (1,918                                       | ) | \$ 2,609                     |
| Year Ended December 30, 2016  |                                    |  |                                     |   |   |                              |
| Allowance for bad debt        | \$ 838                             | \$443                                  | \$ -                                | \$ (358   | ) | \$ 923                       |
| Allowance for contract losses | \$ 1,954                           | \$-                                    | \$ 2,009                            | \$ (1,469                                       | ) | \$ 2,494                     |

<sup>(1)</sup> Balance includes currency translation adjustments.

Recoveries of accounts receivable previously written off were \$28,000, \$84,000 and \$114,000 for fiscal years 2018, 2017 and 2016, respectively.

Schedules other than above have been omitted since they are either not required, not applicable, or the information is otherwise included in the Report.

## EXHIBIT INDEX

The following exhibits are filed as part of, or incorporated by reference into (as indicated parenthetically), the Annual Report on Form 10-K. Unless otherwise indicated all filings are under SEC File Number 000-18655:

- 3.1(i) Restated Certificate of Incorporation of the Company (incorporated by reference from the Company's Registration Statement on Form S-1 as filed on June 25, 1990, registration number 33-35562).
- 3.1(ii) Certificate of Amendment of Restated Certificate of Incorporation of the Company (incorporated by reference from the Company's Current Report on Form 8-K filed on May 24, 2006).
- 3.1(iii) Certificate of Amendment of Restated Certificate of Incorporation of the Company (incorporated by reference from the Company's Current Report on Form 8-K filed on May 28, 2015).
- 3.1(iv) Certificate of Amendment of Restated Certificate of Incorporation of the Company (incorporated by reference from the Company's Current Report on Form 8-K filed on May 31, 2018).
- 3.2(i) Amended and Restated Bylaws of the Company, as amended and restated May 29, 2014 (incorporated by reference from the Company's Current Report on Form 8-K as filed on May 30, 2014).
- 4.1 Specimen copy of Common Stock Certificate of the Company (incorporated by reference from the Company's Registration Statement on Forms S-1 as filed on June 25, 1990, registration number 33-35562).
- \*10.6 Exponent, Inc. 1998 Non Statutory Stock Option Plan dated October 24, 1998 (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 1999).
- \*10.10 Exponent, Inc. 1999 Stock Option Plan (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 1999).
- \*10.11 Exponent, Inc. 1999 Restricted Stock Plan (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 1999).
- 10.15 Commercial Lease No. 03-53542 between the Company and the Arizona State Land Department, effective January 17, 1998 (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended January 3, 2003).
- \*10.17 Exponent Nonqualified Deferred Compensation Plan (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2004).
- \*10.19 Form of Indemnification Agreement entered into or proposed to be entered into between the Company and its officers and directors (incorporated by reference from the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2006).

10.20 Services Agreement between the Company and Exponent Engineering P.C. (incorporated by reference from the Company's Quarterly Report on Form 10-Q for the fiscal period ended March 31, 2006).

\*10.24 Amendment No. 1 to Exponent, Inc. 1998 Nonstatutory Stock Option Plan dated January 29, 2007 (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2006).

\*10.25 Amendment No. 1 to Exponent, Inc. 1999 Stock Option Plan dated January 29, 2007 (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2006).

\*10.26 Amendment No. 1 to Exponent, Inc. 1999 Restricted Stock Plan dated January 29, 2007 (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended December 29, 2006).

\*10.28 2008 Employee Stock Purchase Plan (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 2009).

Form of Restricted Stock Unit Employee Bonus Grant Agreement under the 2008 Equity Incentive Plan  
\*10.31 (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 2009).

Form of Restricted Stock Unit Employee Matching Grant Agreement under the 2008 Equity Incentive Plan  
\*10.32 (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 2009).

Form of Restricted Stock Unit Director Grant Agreement under the 2008 Equity Incentive Plan (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 2009).  
\*10.33

Amended and Restated Restricted Stock Unit Bonus Grant Agreement under the 1999 Restricted Stock Plan  
\*10.34 (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 2009).

Amended and Restated Restricted Stock Unit Matching Grant Agreement under the 1999 Restricted Stock Plan  
\*10.35 (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 2009).

Amended and Restated Restricted Stock Unit Director Grant Agreement under the 1999 Restricted Stock Plan  
\*10.36 (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 2009).

Exponent, Inc. Amended and Restated 2008 Equity Incentive Plan (filed as Appendix A to the Company's Schedule 14A filed on April 19, 2012).  
\*10.37

Exponent, Inc. 401(k) Savings Plan, as amended and restated effective January 1, 2010 (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2010).  
\*10.38

First Amendment to the Exponent, Inc. 401(k) Savings Plan (as amended and restated January 1, 2010)  
\*10.39 (incorporated by reference from the Company's Quarterly Report on Form 10-Q for the fiscal period ended July 1, 2011).

Second Amendment to the Exponent, Inc. 401(k) Savings Plan (as amended and restated January 1, 2010)  
\*10.40 (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2011).

Form of Stock Option Agreement under the 2008 Equity Incentive Plan (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2011).  
\*10.41

Third Amendment to the Exponent, Inc. 401(k) Savings Plan (as amended and restated January 1, 2010)  
\*10.42 (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2012).

Amendment to Form of Stock Option Agreement under the 2008 Equity Incentive Plan (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2012).  
\*10.43

Fourth Amendment to the Exponent, Inc. 401(k) Savings Plan (as amended and restated January 1, 2010)

\*10.44 (incorporated by reference from the Company's Annual Report on Form 10-K for the fiscal year ended January 3, 2014).

Form of Indemnification Agreement entered into or proposed to be entered into between the Company and its

\*10.45 officers and directors (incorporated by reference from the Company's Current Report on Form 8-K as filed on May 30, 2014).



\*10.46 Executive Compensation Clawback Policy (incorporated by reference from the Company's Quarterly Report on Form 10-Q for the fiscal period ended September 30, 2016).

\*10.47 Exponent, Inc. Amended and Restated 2008 Equity Incentive Plan (filed as Appendix A to the Company's Schedule 14A on April 18, 2017).

\*10.48 Exponent, Inc. Amended and Restated 2008 Employee Stock Purchase Plan (filed as Appendix B to the Company's Schedule 14A on April 18, 2017).

21.1 List of subsidiaries.

23.1 Consent of Independent Registered Public Accounting Firm.

31.1 Certification of Chief Executive Officer pursuant to Rule 13a – 14(a) of the Securities Exchange Act of 1934.

31.2 Certification of Chief Financial Officer pursuant to Rule 13a – 14(a) of the Securities Exchange Act of 1934.

32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.

32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.

101.INS XBRL Instance Document

101.SCHXBRL Taxonomy Schema Document

101.CALXBRL Taxonomy Calculation Linkbase Document

101.LABXBRL Taxonomy Label Linkbase Document

101.PRE XBRL Taxonomy Presentation Linkbase Document

101.DEF XBRL Taxonomy Definition Linkbase Document

\* Indicates management compensatory plan, contract or arrangement

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EXPONENT, INC.  
(Registrant)

Date: February 22, 2019 By: /s/ Richard L. Schlenker, Jr.  
Richard L. Schlenker, Jr., Executive Vice President,  
Chief Financial Officer and Corporate Secretary

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

| <b>Signature</b>   | <b>Title</b>   | <b>Date</b>          |
|--|--|----------------------|
| /s/ Catherine Ford Corrigan<br>Catherine Ford Corrigan,<br>Ph.D. | Chief Executive Officer and Director<br><br>(Principal Executive Officer)  | February 22,<br>2019 |
| /s/ Richard L. Schlenker, Jr.<br>Richard L. Schlenker, Jr.       | Executive Vice President, Chief Financial<br>Officer and Corporate Secretary (Principal Financial and Accounting<br>Officer) | February 22,<br>2019 |
| /s/ Paul R. Johnston<br>Paul R. Johnston, Ph.D.                  | Executive Chairman of the Board of Directors   | February 22,<br>2019 |
| /s/ Carol Lindstrom<br>Carol Lindstrom                           | Director   | February 22,<br>2019 |
| /s/ Karen A. Richardson<br>Karen A. Richardson                   | Director   | February 22,<br>2019 |

Edgar Filing: EXPONENT INC - Form 10-K

/s/ John B. Shoven  
John B. Shoven, Ph.D.

Director

February 22,  
2019

/s/ Debra L. Zumwalt  
Debra L. Zumwalt

Director

February 22,  
2019